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The recently advanced quantitative proteomics approaches enabled the 
possibility of direct comparison of protein expressions for multiple samples in 
a high-throughput manner. Besides measuring the protein abundance changes, 
another important topic in proteomics is to provide direct information on 
protein activity and protein interaction, including protein-protein and 
protein-small molecule interactions. The emerging chemical proteomics offers 
a means to systematically analyse the protein activity and small molecule 
interaction other than protein abundance alone. In the first part of this thesis, 
we described a newly developed quantitative chemical proteomics approach 
which allows unbiased and specific drug target profiling. Using this method, a 
spectrum of specific targets of Andrographolide (Andro) was identified, 
revealing the mechanism of action of the drug and its potential novel 
application as a tumor metastasis inhibitor, which was validated through cell 
migration and invasion assays. Moreover, the target binding mechanism of 
Andro was unveiled with a combination of drug analogue synthesis, protein 
engineering and mass spectrometry-based approaches and the drug-binding 
sites of two protein targets, NF-B and actin, were determined. In the second 
part of this thesis, we present a novel method to determine the autophagic 
protein degradation level using chemical metabolic labeling. The sensitivity 
and accuracy of this new methodology was validated using different 
autophagy induction and inhibition approaches. The two projects, though 
independent of each other, have both demonstrated the critical role that 
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Proteins are basic structural scaffolds, playing various important roles in 
living organisms. The large scale “omics” study, especially proteomics, is 
continuing to provide important insights into various biological processes. 
With the increasing sensitivity of modern mass spectrometry platform, 
thousands of proteins and numerous posttranslational modifications can be 
examined simultaneously in any biological system. The recently advanced 
quantitative proteomics approaches enabled the possibility of direct 
comparison of protein expressions for multiple samples in a high-throughput 
manner. These methods already play important roles in biomarker discovery, 
drug treatment perturbation and disease mechanism studies. Besides 
measuring the protein abundance changes, another important area in 
proteomics is to provide direct information on protein activity and protein 
interaction, including protein-protein and protein-small molecule interactions. 
The emerging chemical proteomics offers a means to systematically analyse 
the protein activity and small molecule interaction other than protein 
abundance alone. This chapter will give a brief overview of the currently 
available quantitative proteomics methods as well as the emerging chemical 
proteomics technology. Much attention will be focused on stable isotope-based 
quantitative proteomics, drug target identification and metabolic labeling of 










1.2 Proteome and proteomics  
The term “proteome” is referred to as the entire proteins expressed in cells, 
tissue or organism at a certain time or under defined conditions. Proteomics is 
the large-scale study of the whole proteome, particularly their identity, 
expression patterns, activity and functions. Such information is extremely 
critical for unveiling the mechanism of disease, and designing for the 
diagnostic technique and therapeutic approaches (Mann et al., 2003; Abersold 
et al., 2001). The initial use of conventional proteomics research was mainly 
to identify and characterize proteins. With the advancement in 
chromatography and stable isotope labeling methods, Mass spectrometry (MS) 
and bioinformatics, proteomics has been extended to quantitative and 
comparative studies with wider applications (Figure 1.1), which are now 
playing important roles in biomarker discovery, drug treatment perturbation 
and disease mechanism studies (Lindsay, M.A. et al. 2003). 
 
 




Besides measuring the differences in protein abundance under different 
conditions, another important area in proteomics is to provide direct 
information on protein activity and protein interaction, including 
protein-protein and protein-small molecule interactions. However, protein 
activity at cellular level does not always directly correlate with its abundance, 
thus the traditional proteomics methods are unable to provide such activity 
information. 
To overcome these limitations, a chemical proteomics strategy has been 
introduced that utilize synthetic small molecules to enrich and distinguish the 
interactive biding partners. This strategy offers a means to systematically 
analyse the protein activity and small molecule interaction other than protein 
abundance alone. It has been widely used in drug target identification and 
small molecule function study (Figure 1.1) (Harding, et al., 1989; Brown, et al., 
1994). 
The first key step in proteomics is the effective separation of proteins or 
peptides from a complex mixture (Wu, W.W., et al., 2006). This is usually 
achieved by either gel-based or liquid chromatography (LC)-based strategies 
(Figure 2). The gel-based approach (Fig. 2 left side) is the traditional one but 
still widely used in many studies, as it does not require very expensive 
equipment and can be easily set up in most laboratories. In this approach, 
proteins are first separated basing on two different parameters (pI & MW) and 
then excised, digested and identified using mass spectrometry. It allows direct 
visualization of the separated proteins and their isoforms after different post 
translational modifications. Another widely used strategy in proteomics is 
liquid chromatography coupled with mass spectrometry (LC-MS) (Figure 2, 
right side). Different from the earlier approach, the proteins are not separated 
before identification. The protein mixture is digested into peptides, which are 
subsequently separated by liquid chromatography and identified by mass 
spectrometry.  
In the following sections, the Gel-based and LC-based quantitative 
 4 
 


































Figure 1.2  Two major strategies for protein identification. 
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1.3 Gel based Proteomics and Two Dimensional Gel 
Electrophoresis (2-DE) 
 
Currently, the most widely used methods for profiling and quantitative 
proteomics include the gel-based approaches such as two-dimensional gel 
electrophoresis (2-DE). In 2-DE, proteins are separated by isoelectric focusing 
(IEF) according to their isoelectric points (pI) in the first dimension. Then, 
Proteins migrate on SDS-PAGE according to their molecular weights in the 
second dimension (Hanash, S., 2001). After 2-DE separation, the proteins can 
be easily visualized by staining or fluorescent scanning. Normally, we can 
easily separate and visualize 1000 proteins using 2-DE (Figure 1.3). When 
combining multiple narrow PH range gels, it even enables distinguishing up to 
5000 proteins (Hoving, et al. 2000). The quantitation is achieved by 
comparing the protein expression levels (intensity of the proteins spots) of 
different sample pairs (normal versus diseased samples, cells at different 
stages or under different treatments, etc.) using a software. The differentially 
expressed proteins can then be excised and identified subsequently using mass 
spectrometry. However, the efficiency of proteins transferred from IEF to the 
second dimension SDS PAGE usually varies from gel to gel, and thus it is 
difficult to differentiate the real expression changes from the system errors. 
The poor reproducibility of 2-DE emphasized the need of a number of 
replicate gels of the same protein sample in order to avoid experimental errors 
(Righetti, P.G., et al.,2004). Besides the tedious process and waste of samples, 
the accuracy of this method still can not be guaranteed. 
To overcome this issue, difference gel electrophoresis (DIGE) was 
developed by Unlu et al. (1997), where the control and treated samples are 
independently labeled with two structurally similar fluorescent dyes (e.g., Cy3 




Figure 1.3  Two Dimensional Gel Electrophoresis (2-DE) separation of 
HCT116 whole proteome. After isoelectric focusing (IEF), the proteins are 
separated according to their sizes using SDS PAGE. Proteins can be visualized 
by staining (silver stained gel, unpublished data). 
 
 
and separated in a same 2-D gel to minimize gel-to-gel variations and improve 
the reproducibility of the samples. 2D-DIGE technology is based on the 
development of the fluorescent protein labeling dye (Cy2, Cy3 and Cy5), 
which are identical both in mass and charge. Therefore, the same proteins 
labeled with different dyes from biological samples will migrate in the same 
pattern on 2-D gel. Consequently, this method allows two or even up to three 
samples directly compared in a single run. 2D-DIGE has dramatically 
improved the sensitivity and reproducibility of gel-based proteomics. However, 
the gel-based approaches still suffer from the difficulties in detecting several 
types of proteins, including membrane associated proteins, low-abundant 
proteins and proteins with extreme PI and size (Corthals, G.L. et al. 2000; 





1.4 LC-MS/MS based proteomics and quantitative proteomics  
 
Besides gel-based proteomics, LC-based proteomics has been developed 
and has drawn increasing attentions in the last decade. Compared with 
gel-based approaches, LC-based methods have several prominent advantages, 
such as high sensitivity and reproducibility, capability of identifying 
low-abundant proteins (Gygi, S.P., et al., 2000), highly acidic or basic proteins 
or proteins with extreme size or hydrophobicity. Furthermore, LC-based 
methods can be operated automatically to handle the high-throughput samples 
(Hamdan, M. and P.G. Righetti, 2002). 
LC-based approaches adopt a variety of combination of stationary and 
mobile phases to separate complex proteomics samples at peptide level (Issaq, 
H.J., et al., 2005; Shi, Y., et al., 2004). Proteins are first digested into peptides 
using a protease (usually trypsin). In most cases, the resulting peptide mixture 
is extremely complex. Multi-dimensional LC is needed instead of single LC. 
The widely used combination is strong-cation exchange (SCX) followed by 
C18 reversed-phase LC coupled with mass spectrometer. 
For relative quantification of proteins or peptides using LC-MS, several 
stable isotope tagging methods are available. Stable isotopes have the same 
physico-chemical properties as the natural atoms and the incorporated proteins 
are almost identical to their natural counterparts. In practice, isotope labeling 
can be achieved by metabolic incorporation or chemical tagging. The 
difference in peptides masses enables the determination of the relative 
quantities of a peptide in different samples. Other than stable-isotope labeling 
approach, several label-free methods have also been developed (Wu,W, et al., 
2006; Liu, H., R.G. Sadygov, et al., 2004; Chelius, D., et al.,2003). For better 
understanding, a brief overview on LC-MS based quantitative methods, 
including SILAC, ICAT and iTRAQ, is provided in the following sections. 
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1.4.1 Stable isotope labeling by amino acids in cell culture 
(SILAC) 
 
Established by Mann and co-workers in 2002 (Ong, S. et al.,2002), stable 
isotope labeling by amino acids in cell culture (SILAC) has now been widely 
used for protein abundance quantification in LC-MS/MS-based platform. 
SILAC is an in vivo metabolic labeling method for mass spectrometry 
(MS)-based quantitative proteomics. The principal of SILAC is that the 
growth of mammalian cells needs essential amino acids (e.g. arginine, 
methionine, lysine, leucine) from external source. Two cell populations are 
grown either in normal conditions (“light” - natural amino acids) or with stable 
isotope labeled essential amino acids (“heavy” amino acids - 13C labeled 
L-arginine and 13C, 15N-labeled L-lysine, etc.) (Figure 1.4). The heavy-isotope 
labeled amino acids are incorporated into all newly synthesized proteins instead 
of the natural amino acids. After a number of cells divisions, the “light” and 
“heavy” amino acids can be fully incorporated into the whole proteome. Since 
the properties of isotopes labeled amino acid is almost the same as the natural 
amino acid, the cells behave exactly like the control cells grown with the natural 
amino acid. In MS process, there will be a mass shift of 6 Da for 
13C-L-arginine-labeled peptides and 8 Da for 13C, 15N-L-lysine-containing 
peptides when comparing the mass spectra of “heavy” and “light” peptides 
due to the use of isotope-labeled amino acids. These isotope-labeled peptide 
pairs behave identically during their isolation, separation, and ionization as the 
isotopic amino acids have the same physicochemical properties. Thus, the 
relative quantification of the “heavy” to the “light” peptides can be achieved 
by comparing the ratio of ion intensities of the SILAC peptide pairs. This ratio 
of peptides reflects the ratio of protein abundance in the original sample pair 
compared (Ong, S.E., et al., 2002; Martinović, S., et al., 2002; Ong, S.E., et al., 
2003). Nevertheless, due to the inherent limitation of SILAC, such an 
approach takes a long time for complete incorporation of isotopic amino acids, 
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thus it may not be suitable for certain cells that cannot be maintained for a 
long time, such as platelets. Furthermore, it is also extremely difficult to apply 
the SILAC approach to tissue and body fluid samples, which are of particular 
relevance to biomedical research. In such cases, the after-mentioned chemical 
labeling is the alternative choice for protein quantification. Moreover, SILAC 
only allows the quantification of at most 3 samples at one time. Thus it is 
difficult to compare more than 3 different conditions like series of time points 
or dosages and it is impossible to include biological duplicate samples in the 
same LC MS/MS run. Alternatively, isobaric tags for relative and absolute 
quantification (iTRAQ) can be considered as iTRAQ can simultaneously 











1.4.2 Isotope-coded affinity tags (ICAT) 
Recently developed isotope-coded affinity tags (ICAT) is another method 
for quantitative protein profiling (Gygi S.P. et al. 1999). The ICAT reagents 
consist of a biotin affinity tag, an isotopically labeled linker and a 
thiol-specific reactive group (iodoacetamide) which is specific for sulfhydryl 
groups (Figure 1.5A) (Brown, G., et al., 2003). By using this paired 
thiol-specific ICAT reagent, the side chains of cysteine residues in a reduced 
protein sample can be labeled with isotopically light reagent. And the 
equivalent cysteine group in another sample can be labeled with the eight-fold 
deuterated heavy ICAT label representing a second cell state. After combining 
the two light-and heavy-labeled samples followed by trypsin digestion, 
thiol-labeled cysteine containing peptides are enriched through avidin affinity 
chromatography to reduce the complexity. Next, isolated cysteine containing 
peptides are fractionated, and quantitatively analyzed by mass spectrometry 
(Figure 1.5B). In the LC-MS/MS analysis process, the machine can determine 
the quantity of the labeled peptides and analyse the sequence of the peptide 
thus identifying the proteins concurrently. Peaks derived from the same 
peptide appear as doublets in mass spectrum due to the 8 Da mass differences 
between light and heavy labels. The doublet peak intensities of the peptides 
can be compared and used to represent the relative abundance of the proteins 
in the two labeled samples. ICAT can significantly reduce the complexity of 
the mixed samples, thus allowing the determination and identification of 
certain low abundant proteins. Furthermore, ICAT is fully compatible with 
protein derived from body fluids, cells, or tissues under different conditions as 
well as after biochemical, immunological, or physical fractionation and 
treatment. However, ICAT also has several limitations including the missed 
identification of proteins with no or few cysteine residues (96.1% of the 
human proteome contains at least one cysteine), and losing information of 
post-translational modifications (PTM) (Tournigand, C., et al.,2004). Same as 
SILAC, ICAT is also limited by the small sample number (2 samples) that can 
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be analyzed in each run. Moreover, the modification of the peptide by ICAT 
reagent (around 500 Da) is relatively large, which can complicate the 
interpretation of tandem mass spectrometry (MS/MS) spectra due to the 
addition of the biotin group, especially for small peptides (Leitner, A. and W. 
Lindner, 2004; Goshe, M.B. and R.D. 2003). Many of these limitations have 
been overcome by the new cleavable ICAT (cICAT) reagent that employs 13C 
isotopes and an acid-cleavable biotin group (Yu, L.R., et al., 2004; Hansen, 
K.C., et al., 2003). This new version of the reagent can make the enrichment 
and elution of the labeled peptide more efficient and convenient and simplify 
the spectra analyse process. 
 
1.4.3 iTRAQ – Multiplexed chemical tagging for quantitation  
 
Although powerful, aforementioned SILAC and ICAT only allow the 
comparisons between two or three samples at one single LC run. In order to 
overcome this limitation, a 4-plex followed by an 8-plex isobaric quantitative 
labeling technique named iTRAQ has been developed and introduced in 2004 
(Ross, P.L. et al., 2004) and 2007 (Choe, L., et al., 2007) by Applied 
Biosystems.  
8-plex iTRAQ reagents were designed as isobaric tags which consist of a 
reporter group (from 113-121), a mass balance group (carbonyl) and a group 
that reacts with peptides (NHS ester) (Figure 1.6.A). The reagents specifically 
label all the amine groups of the digested peptides through an amide linkage. 
The total mass of the reporter and the balance group are kept identical by 
incorporating different isotopic combinations of 13C, 15N, and 18O atoms, thus 
avoiding problems with chromatographic separation seen with enrichment 
involving deuterium substitution (Choe, L., et al., 2007). The reporter group 











Figure 1.5  Quantitative proteomics by using isotope-coded affinity tag 





balance group has a mass of 184 to 192, thus ensuring the identical total mass 
is 305 for each of the four reagents. When incubating the reagent with the 
peptides, the amine reactive group (NHS ester) forms an amide linkage to the 
peptide amines (N-terminal or ε amino group of lysine). After mixing the 
labelled peptides, the peptides labeled with different iTRAQ tags are eluted 
and ionized as one single MS peak (identical m/z) as they are isobaric. The 
amide linkages formed by iTRAQ reagents are broken in a manner similar to 
backbone peptides bonds when subjected to Collision-induced dissociation 
(CID). Upon MS/MS fragmentation, the balance groups are lost (neutral loss) 
while the reporter groups generate MS/MS signature ions with m/ z 113–121. 
This mass range has rather clean background with almost no contamination 
signals (except m/z 120 for immonium ion of phenylalanine) produced due to 
collision induced dissociation (CID) in Tandem mass spectrometry (MS/MS). 
The quantification of the peptide abundance can be calculated from the 
relative areas of the reporter peaks in each sample (Figure 1.6C). A series of 
strong signature y- and b- ions were also generated to allow highly confident 
protein identification along with peptide quantitation during the MS/MS 
fragmentation process (Ross, P.L. et al., 2004; Zieske, L.R., 2006). Different 
from ICAT, the quantitation of iTRAQ is performed at the MS/MS process 
rather than in MS stage. Using iTRAQ-based quantitative proteomics, up to 
eight samples can be labeled and quantified simultaneously 
In our study, we choose the most versatile labeling approach, iTRAQ for 
comparing the enriched drug interactive proteins from the non-specific 
binding proteins. The detailed methodology and its efficacy are described in 
the following chapter. iTRAQ provides precise and accurate quantitation of up 
to 8 samples simultaneously, allowing the inclusion of the biological replicates 










































Figure 1.6  Structure of iTRAQ reagent (8-plex) and labeling work flow of 
iTRAQ. (A) The structure of iTRAQ reagent. (B) The reaction scheme of 
iTRAQ reagent reacted with amine. (C) The iTRAQ labeling work flow. After 
reduction, alkylation, and digestion, each sample is tagged with a different 




1.5 Emerging Chemical Proteomics 
 
The traditional 2-DE based and gel-free proteomics enable researchers to 
compare the relative protein levels across multiple samples; however, these 
methodologies can only provide the information on protein expression level or 
abundance changes. As a result, these approaches are unable to disclose the 
direct information on protein activity and protein interaction, including 
protein-protein and protein-small molecule interactions, etc. Such information 
is extremely important for the understanding of the structures and functions of 
the proteins, which help people to gain more insights into the complex 
physiological and pathological processes. 
The emerging chemical proteomics offers a means to systematically 
analyze the protein activity and small molecule interaction other than protein 
abundance alone. This multidisciplinary approach makes use of the synthetic 
small molecules that can covalently react with catalytic residues in an enzyme 
active site. The specific activity of the chemically reactive group allows 
specific proteins or protein complex to be tagged, purified, and identified. As a 
result, this technique is able to identify novel enzymatic proteins and has the 
potential to accelerate the discovery of new drug targets. The following 
sections will briefly describe the development of the chemical proteomics 
methods and their applications especially in drug target identification and the 
studies of newly synthesized proteins. 
 
1.5.1 Drug target identification 
 
The majority of drugs exert pharmacological effects by interacting with 
their target proteins. A comprehensive identification of the specific protein 
targets of a drug is a critical step in unravelling the mechanisms of the known 
drug effects and thereby enhancing our understanding of the drug 
pharmacodynamics to refine its clinical application in future. Besides, the 
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identification of molecular targets can also provide the information on 
so-called “off-targets” of compounds and drugs, the unexpected target proteins 
which may lead to unwanted biological activity and toxicity. It should be 
noted that the concept of “polypharmacology” has been accepted by increasing 
researchers recently (Ziegler et al. 2013). People found that actually most of 
the drugs exert their disease modulation effects by simultaneously targeting 
several proteins. And this rocked the concept of “one gene, one drug, one 
disease”(Lounkine et al. 2012).  
Chemical proteomics, a multidisciplinary method which integrate organic 
synthesis with cell biology and mass spectrometry platform, has provided a 
direct and comprehensive way to profiling the targets of a drug and explaining 
its mechanism of action (MOA). The mostly used approaches to identify 
protein targets of a drug typically utilize immobilized drug affinity 
chromatography coupled with mass spectrometry (MS) (Harding, M.W., Galat, 
A., Uehling, D.E., Schreiber 1989; Brown, E.J., Albers, M.W., Tae Bum Shin, 
Ichikawa, K., Keith, C.T., Lane, W.S., Schreiber 1994). In this method, the 
bead-immobilized drugs are incubated with protein extracts followed by 
extensive buffer wash to remove the non-interactive proteins. Next, the 
targeted proteins are released by high amount of free drug or heat denaturation. 
Finally, the bond proteins can be identified using mass spectrometry-based 
proteomics methods. Using these approaches, targets of several important 
drugs and thief mechanisms of action have been successfully disclosed, e.g. 
imatinib, dasatinib, rapamicin, wortmannin, withaferin A, stauprimide, 
thalidomide, and etc. (Ziegler, S. et al., 2013). 
Recently, several excellent studies have utilized the affinity-based drug 
pull down to profile the drug targets and pointed out the side effects of the 
drug or possible mechanism of drug resistance. Handa and his college 
modified thalidomide into affinity beads for enriching its functional targets(Ito 
et al. 2010). They identified cereblon (CRBN) as a thalidomide-targeting 
protein. CRBN and its downstream partner proteins are important for limb 
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development in zebrafish and chicks. Their result reveals the basis for 
thalidomide teratogenicity and may illuminate the development of new 
thalidomide analogues without teratogenic activity. Very recently, Zhang had 
used an immobilized Pyrazinamide (PZA) analogue to study its direct binding 
partners (W. Shi et al. 2011). Pyrazinamide (PZA) is a first-line tuberculosis 
(TB) drug which can shorten the duration of chemotherapy. Using the 
chemical proteomics approach, they identified the ribosomal protein S1 (RpsA) 
as one of the targets possibly through inhibition of trans-translation. They 
found RpsA overexpression correlated with the increased PZA resistance and 
three PZA-resistant clinical isolates harboured RpsA mutations. Their results 
also suggested inhibition of trans-translation may play an important role in the 
anti TB effects. 
Although powerful, these methods can only be applied to cell lysates but 
not an in vivo setting, due to the requirement of a solid support. The in vitro 
target profiling may not accurately reflect the drug’s actions in the 
physiological environment in vivo. To overcome this limitation, several groups 
have used the activity-based protein profiling (ABPP) combined with 
bio-orthogonal click chemistry to identify drug targets both in vitro and in vivo 
(Figure 1.8) (Speers et al. 2003; Ovaa et al. 2003; Evans & Cravatt 2006; 
Nomura et al. 2010; Paulick & Bogyo 2008; Fonović & Bogyo 2008; Böttcher 
et al. 2010; P.-Y. Yang et al. 2010; C.-X. Liu et al. 2012; Shi et al. 2012; 
Willems et al. 2011; Böttcher & Sieber 2008b; Gersch et al. 2012). ABPP 
probes exert their functions by a covalent reaction with the target proteins or 
photoaffinity-based labeling via incorporation of photoreactive groups. With 
the increasing sensitivity of modern MS platform, even low abundance protein 
targets can be successfully identified to explain the MOA of a drug. In the 
following section, I will briefly discuss the ABPP and clickable ABPP 





1.5.2 Activity-based protein profiling 
Activity based protein profiling (ABPP), pioneered by Bogyo, Cravatt and 
others (Speers et al. 2003; Ovaa et al. 2003; Evans & Cravatt 2006; Nomura et 
al. 2010; Paulick & Bogyo 2008; Fonović & Bogyo 2008; Böttcher et al. 2010; 
P.-Y. Yang et al. 2010), is a novel functional proteomics technology to study 
the enzyme activities and targets of mechanism-based suicide small molecules. 
Activity based probes (ABPs) generally possess three basic elements: 1) a 
reactive group (or an electrophilic group) for targeting and covalently labeling 
the active sites of an enzyme; 2) a reporter tag or handle that can be used for 
visualization (e.g. fluorophore), enrichment and identification (e.g., biotin) of 
modified proteins; 3) a flexible linker connecting the reporter and reactive 
group and providing enough space between them. (Figure 1.7) 
 
Activity (Affinity) Based Probe 
 
Figure 1.7  Structure of an Activity (Affinity) based probe. ABP probes 
usually consist of three basic components: a reactive group for covalent 
binding to the target proteins; a linker group to provide enough spacing and 
specificity; and a tag for visualization or purification, identification. For AfBP, 




Normally, ABPs can be categorized into mechanism-based or 
affinity-based probes (AfBP), according to whether a covalent linkage forms 
during the probe binding. For mechanism-based ABPs, the reactive group of 
the probe usually contains an electrophilic structure which can specifically and 
irreversibly react with catalytic residues in the enzyme’s active site thus form 
a very stable adduct. While for the AfBP, the covalent interaction is lacking 
and the drug and targets interacted through the reversible affinity linkage. 
Therefore, a photo-affinity tag (Figure 1.7) can be introduced to the probe 
which can covalently bind to the spatially proximate target proteins upon 





















Figure 1.8  General workflow of target profiling using activity-based probe 
(ABP). The cell lysates are firstly incubated with ABP. Subsequently the 
labeled proteome can be detected by in-gel fluorescence scanning (by 
fluorescence -tagged probes). Alternatively, protein targets can be enriched and 





































The reactive groups of ABPs usually possess an electrophile that can be 
covalently linked to a nucleophilic residue (mainly Ser, Cys or Lys) in the 
active site of an active enzyme. Notably, an enzyme that is inhibited by 
inhibitors or post-translationally modified will not react with an ABP since the 
activity of the enzyme has changed or lost. 
In ABPP proteomics experiment (Figure 1.8), the ABP is incubated with 
the proteome (cell lysate) and the probe will bind to its active targets. Then, 
the probe-labeled proteins can be visualized either by in-gel fluorescence 
scanning (fluorescence-tagged probes) or identified through pull-down 
followed by LC-MS/MS (biotinylated probes). 
A main advantage of ABPP is its capability of profiling the active site of 
the enzyme directly, not limited to only the protein relative abundance. Thus 
far, various ABPP probes have been developed for several enzyme classes, 
such as cysteine proteases, metalloproteases (Saghatelian, et.al, 2004), and 
serine hydrolases (Liu, Patricelli, & Cravatt, 1999). This method has a great 
advantage over traditional methods that depend on abundance rather than 
activity.  
When combined with tandem mass spectrometry, ABPP allows the 
identification of various active enzymes or drug targets simultaneously from a 
single sample. This technique has been used increasingly in drug discovery 




1.5.3 Tandem bio-orthogonal labeling and Click chemistry for 
probe design 
The attachment of the affinity or fluorescent tag in ABPP usually 
restricted the application scope of ABPP for in vivo study due to the low cell 
permeability of the commonly used tags. However, during the cell lysis 
process, various activators and inhibitors which influence the enzyme activity 
are often released due to the disruption of the cell compartments. As a result, 
the in vitro target profiling may be different and not accurately reflect the 
drug’s actions in the physiological environment in vivo. In order to retain the 
drug activity and make the drug still cell permeable, minimal modification 
should be used when introducing the tags into the drug. This issue can be 
solved by using the bio-orthogonal chemistry methods, such as Staudinger 
ligation between azides and phosphines (Figure 1.9A) or copper(I)-catalyzed 
Huisgen-[3+2]-azide-alkyne cycloaddition (often referred to as “click” 












Azide modified drug or protein
Phosphine linked tags  
 
 
Figure 1.9  Click chemistry and Staudinger ligation. (A) Staudinger ligation. 





These bio-orthogonal tags (normally an azide or alkyne group) are small 
enough so that introducing these tags to drugs normally will not affect the cell 
permeability of the drug significantly. Staudinger-Bertozzi ligation was first 
introduced by Bertozzi in chemical biology and was initially used to profiling 
glycosylated proteins on cell surfaces. Although specific, however, this 
reaction suffers from phosphine oxidization and slow reaction kinetics (Sletten, 
E. M.,2009). Alternatively, “click” chemistry is a rapid reaction, through 
which azide can undergo Cu (I)-catalyzed [3+2] cycloaddition with terminal 
alkynes to yield the stable triazole conjugates. This reaction can easily proceed 
in aqueous environments and exhibit extremely high selectivity with its 
partner thus is called ‘bio-orthogonal’ reaction. (Prescher J.A., et al. 2005). 
Therefore, we can first label the target proteins in living cells by using this 
cell-permeable clickable probe, and following cell lysis, tag them with the 




Figure 1.10  General workflow of the targets profiling using “clickable” 





1.5.4 Chemical metabolic labeling with unnatural amino acid  
 
In chemical proteomics, besides utilizing the small molecule probes to 
delineate the interactive partners, another emerging field involves using 
chemically modified unnatural metabolites to study the dynamic protein 
synthesis or post-translational modification. Recently, a novel technique for 
labeling newly synthesized proteins has been developed by Tirrell and 
colleagues (Dieterich, Link et al. 2006). In this method, L-azidohomoalanine 
(AHA), an amino acid analog of methionine containing an azide moiety, can 
be incorporated into newly synthesized proteins without any manipulations 
and can be readily detected by a aforementioned “click chemistry” between an 
azide and alkyne-bearing tags (Dieterich, Link et al. 2006). Briefly, this 
approach involves two subsequent steps. During the first step, similar to the 
traditional metabolic labeling with radioactive amino acids (35S-labeled 
methionine or cysteine), AHA is incubated with the cells or organisms and 
incorporated into newly synthesized proteins by cellular machinery. This azide 
tag allows distinguishing metabolically labeled proteins from unlabled 
proteins. While in the second step, the azide bearing unnatural amino acid 
AHA is covalently tagged with a fluorescent tag or biotin tag through 
bio-orthogonal click chemistry (Figure 1.11A and B). In combination with 
fluorescent tagging and detection, the newly synthesized proteins can be 
conveniently visualized by microscopic imaging or in-gel fluorescent scanning. 
Alternatively, the AHA labeled proteins can be “clicked” with biotin tags for 
affinity enrichment. After affinity purification using avidin beads and trypsin 
digestion, the peptides can be identified by mass spectrometry (Dieterich, Link 
et al. 2006; Dieterich, Lee et al. 2007). As reported, the incorporation of AHA 
is non-toxic to the cell. Besides, AHA will not affect the global rates of protein 
synthesis and degradation. Based upon this convenient technique, the 
metabolic labeling of AHA into newly synthesized proteins has been widely 
used in mammalian cells (Dieterich, Link et al. 2006), primary neuronal cells, 
brain slice cultures (Dieterich, Hodas et al.) and larval zebrafish (Hinz, 
 24 
 
Dieterich et al.).  
Very recently, Eichelbaum and Krijsveld utilize the AHA labeling to study 
the secreted proteins. They incubated the cells with a pulse of AHA, which 
enables the possibility to selectively enrich newly synthesized proteins secreted 
into the cell medium. At the same time, they also applied pulsed SILAC 
(pSILAC) to label two parallel cell populations with either intermediate- or 
heavy- arginine and lysine for a precise time window. Thus, they were able to 
quantify the relative abundance of the newly secreted proteins (Eichelbaum, 
Winter, Krijgsveld, 2012). In another recent study, Howden and Acuto 
demonstrated the ability to quantify stimuli-induced proteome dynamics in 
primary cells by combining AHA and SILAC labeling. In their study, they 
were able to determine the early expression level changes of >600 proteins in 




















Figure 1.11  AHA labeling of newly synthesized proteins. AHA labeling of 
newly synthesized proteins. (A) Structure of azidohomoalanine (AHA), an 
analog of methionine containing an azide moiety. (B) Click azide/alkyne 
reaction. The azide and alkyne moieties are interchangeable, where the 






The aim of my thesis is to advance the application of quantitative and 
chemical proteomics in drug target identification and autophagic proteolysis 
research. For the first aim, the drug target identification approach we 
developed should be unbiased and could offer a means to specifically and 
comprehensively identify drug targets in live cells. It is hoped that this method 
can be widely applied in drug development and optimization to refine the 
therapeutic potentials of drugs by uncovering knowledge on their specific 
targets and mechanisms of action. The specific target of andrographolide will 
be identified using this newly developed method and validated through 
different bio-assays. In the second part, we developed a novel method to 
determine the autophagic protein degradation level using metabolic labeling. 
This novel method should be simple, sensitive, and specific for measuring 
autophagic protein degradation and could be easily adapted for high 







  Chapter 2
 
A Quantitative Chemical Proteomics Approach to Profile the 
Specific Cellular Targets of Andrographolide, a Promising 
Anticancer Agent that Suppresses Tumor Metastasis 
 
2.1 Summary  
 
Drug target identification is a critical step towards the understanding of 
the mechanism of action of a drug, which will help to improve the current 
therapeutic regime and to expand the drug’s therapeutic potential. However, 
current in vitro affinity chromatography-based and in vivo activity-based 
protein profiling (ABPP) approaches generally face difficulties discriminating 
specific drug targets from non-specific ones. In this chapter, we describe a 
novel approach combining isobaric tag for relative and absolute quantitation 
(iTRAQ) with Clickable ABPP, named ICABPP, to specifically and 
comprehensively identify the protein targets of andrographolide (Andro), a 
natural product with known anti-inflammation and anti-cancer effects, in live 
cancer cells. We identified a spectrum of specific targets of Andro, which 
furthered our understanding of the mechanism of action of the drug. We found 
that Andro has a potential novel application as the tumor metastasis inhibitor, 
which was validated through cell migration and invasion assays. Moreover, we 
have unveiled the target binding mechanism of Andro with a combination of 
drug analogue synthesis, protein engineering and mass spectrometry-based 
approaches and determined the drug-binding sites of two protein targets, 
NF-B and actin. 
2.2 Introduction  
 
As most drugs exert pharmacological effects by interacting with their 
target proteins, identification of which is a critical step in unravelling the 
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mechanisms of drug action. It is also imperative for our understanding of the 
pharmacodynamics of a known drug, suggesting the potentially unrevealed 
actions and thus refining its future clinical applications. Traditional approaches 
to identify protein targets of a drug typically utilize immobilized drug affinity 
chromatography coupled with mass spectrometry (MS) (Harding, M.W., Galat, 
A., Uehling, D.E., Schreiber 1989; Brown, E.J., Albers, M.W., Tae Bum Shin, 
Ichikawa, K., Keith, C.T., Lane, W.S., Schreiber 1994). These methods can 
only be applied to cell lysates but not an in vivo setting, due to the requirement 
of a solid support. Thus, the in vitro target profiling may not accurately reflect 
the drug’s actions in the physiological environment in vivo. To overcome this 
limitation, several groups have used the activity-based protein profiling 
(ABPP) combined with bio-orthogonal click chemistry to identify drug targets 
both in vitro and in vivo (Figure 2.1) (Speers et al. 2003; Ovaa et al. 2003; 
Evans & Cravatt 2006; Nomura et al. 2010; Paulick & Bogyo 2008; Fonović 
& Bogyo 2008; Böttcher et al. 2010; P.-Y. Yang et al. 2010; C.-X. Liu et al. 
2012; Shi et al. 2012; Willems et al. 2011; Böttcher & Sieber 2008b; Gersch et 
al. 2012). ABPP probes exert their functions by a covalent reaction with the 
target proteins or photoaffinity-based labeling via incorporation of 
photoreactive groups. With the increasing sensitivity of modern MS platform, 
low abundance protein targets can be successfully identified. Although both 
the conventional affinity chromatography and recent ABPP-based methods 
allow us to detect a set of candidate protein targets for a drug, it remains 
difficult to discriminate specific interactions from non-specific ones. Hence, 
more time and effort are needed for subsequent validation due to the presence 
of a large number of non-specific binders. Therefore, there is an urgent need to 
develop comprehensive unbiased methods for specific target identification. 
Quantitative proteomics has been used to profile enriched kinases using cell 
lysate-based kinobead pull-down. However, these types of experiments are 
mainly suitable for studying kinase inhibitors(Bantscheff et al. 2007). Recently, 





Figure 2.1  General workflow of the potential cellular targets profiling using cell-permeable, activity-based Andro probe. The live 
cells are firstly incubated with Andro probes followed by cell lysis. Subsequently the labeled proteome are clicked with fluorescent 
dye to allow visualization of target proteins by SDS-gel. Alternatively, protein targets can be fished out with biotin azide and 
identified using MS/MS. 
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binders of small molecules or proteins with certain post-translational 
modifications (Sharma et al. 2009; Ong et al. 2009; Li et al. 2012). These 
studies shed light on how quantitative proteomics can improve the specificity 
of the target protein identification. Nevertheless, due to the inherent limitation 
of SILAC, such an approach takes a long time for complete incorporation of 
isotopic amino acids. Furthermore, it is also extremely difficult to apply the 
SILAC approach to tissue and body fluid samples, which are of particular 
relevance to biomedical research.  
Here we introduce an isobaric tag for relative and absolute quantitation 
(iTRAQ)-based Clickable ABPP (ICABPP) approach for unbiased, specific 
and comprehensive identification of target proteins in live cells. iTRAQ is a 
stable-isotope labeling approach for multiplexed quantitative proteome 
profiling (Ross et al. 2004). An overview of the technique is illustrated in 
Figure 2.2a. In this assay, cells are first incubated with a clickable probe or 
with DMSO, which serves as a negative control. After the probe permeates the 
cell and covalently binds to its dedicated in situ targets, the washed cells are 
lysed, clicked with biotin-N3 tag and enriched through avidin pull-down in 
parallel. The beads are washed thoroughly and the bond proteins are directly 
digested on beads with trypsin. The resulting peptides are labeled with 
respective iTRAQ reagents, and pooled together for further identification and 
quantification by LC-MS/MS. This technique enabled us to discriminate 
specific protein targets from non-specific and endogenously biotinylated 
proteins. Biological replicates of probe- or DMSO-treated samples are 
included to overcome experimental variations. As shown in Figure 2.2b, 
non-specific binding proteins’ iTRAQ reporters have equal or similar 
intensities, whereas specific target proteins enriched by the probe show highly 
differential intensities compared to DMSO-treated control samples (as 
illustrated by the significantly higher reporter intensities of 116 and 117 vs. 
113 and 114 shown in Figure 2.2b). The multiplexing nature of iTRAQ-based 
chemical proteomics method allows replicated enrichments to be compared 
within a single LC-MS/MS analysis, hence increasing the accuracy of 




Figure 2.2  Identifying specific drug targets using ICABPP approach in live 
cells. a) Live cells were treated with DMSO and clickable probe in duplicates. 
Cells were lysed and tagged with biotin-N3 using click chemistry in parallel. 
The biotin bearing target proteins were enriched through avidin pull-down and 
directly digested on beads. The resulting peptides of the two biological 
replicates of control pulled-down samples were labeled with 113 and 114, 
respectively, and two probe pulled-down samples were labeled with 116 and 
117, respectively. The labeled peptides were combined together to be 
identified and quantified by LC-MS/MS. b) For the non-specific targets, the 
iTRAQ reporters show similar intensities, while for the specific targets, the 
reporters show highly differential intensities.  
 
 
In this context, ICABPP approach was applied to identify protein targets 
of andrographolide (Andro, Figure 2.3), a natural product with known 
anti-inflamation and anti-cancer effects, (Bao et al. 2009; Zhou et al. 2006; 
Zhou et al. 2010; Zhou et al. 2008; Jada et al. 2008) in live cancer cells. A 
spectrum of 75 potential Andro targets was identified with high confidence, 
which suggested that Andro may exert anti-cancer effects by acting on 
multiple targets to interfere with several cellular signaling pathways. Two 
targets, NF-B and β-actin were validated by in vitro binding assay and direct 
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binding site mapping. Furthermore, our data revealed a novel mechanism of 
Andro in suppressing tumor metastasis. 
 
 
Figure 2.3  Chemical structures of Andro, reduced Andro analogue RA and 








































Scheme 2.3  The synthetic scheme for P2. 
 
2.3 Results and Discussion 
2.3.1 Design and synthesis of Andro-based probes 
Ideally, the active moiety of Andro must be retained in the newly designed 
Andro-based ABPP probe and the attached tag should not affect its interaction 
with cellular targets during live cell labeling. However, the active moiety and 
precise mode of action of Andro remain largely elusive. Xia et al. previously 
reported that Andro binds covalently to Cys62 of NF-B p50 (Bao et al. 2009; 
Wang et al. 2007; Xia et al. 2004). Based on this known interaction, we 
postulated that the α,β-unsaturated γ-lactones might be involved in the protein 
alkylation. The reduced form of Andro analogue RA (Figure 2.3, synthetic 
scheme shown in Scheme 2.1) was synthesized to test its biological activity 
against the colorectal cancer cell line HCT116, which is known to be sensitive 
to Andro treatment (Zhou et al. 2010; Jada et al. 2008). Our results suggested 
that Andro had potent anti-cancer effect on HCT116 cell line with IC50 of 31 
µM, as well as MV4-11, HeLa and HepG2 cell lines (Table 2.1). When the 
C12-C13 double bond of Andro was reduced to a single bond, the analogue 
RA completely lost its cancer inhibitory potency even up to 100 µM 
 34 
 
concentration (Figure 2.4), suggesting that the α,β-unsaturated γ-lactones and 
the covalent protein binding of Andro are critical for its anti-cancer property. 
Previous structure-activity relationship studies suggested that the ester 
derivative of Andro at C14 hydroxyl group did not affect the C12-C13 moiety 
and the drug’s potency (Das et al. 2010; Nanduri et al. 2004; Wang et al. 2010). 
Therefore, we introduced an alkyne handle using the ester linkage at C14 
position to synthesize the clickable probe P1 (Figure 2.3, synthetic scheme 
2.2). At the same time, to overcome the limitation of the instability of the ester 
bond, another probe P2 with amide bond linkage was also synthesized. This 
probe would have better in vitro and in vivo stability, as it would be less prone 
to breakage or hydrolysis. (Figure 2.3, Synthetic scheme 2.3). Because the 
introduction of amino group partially reverted the configuration of C14 during 
the synthesis, P2 was a mixture of two isomers with the ration of 1:0.8. We did 
not separate these two isomers as we found that the anti-cancer activity was 
still retained (vide infra). To investigate whether the structural modifications 
would influence the anti-cancer potency of the probe, we conducted in vitro 
growth inhibitory assay on HCT116 using P1 and P2. Our data confirmed that 
P1 and P2 still possess antiproliferative activity (Figure 2.4). Therefore, both 









Table 2.1  IC50 values of Andro in HCT116, MV4-11, HeLa, and HepG2 cell 
lines. Each cell line was treated with Andro in various concentrations for 48 h. 
The IC50 values of Andro in HCT116, HeLa, and HepG2 cell lines were 
determined using crystal violet assay. The IC50 value of Andro in MV4-11 was 
determined using Propidium Iodide (PI) staining and flow cytometry. 
 
Cell line IC50 Tissue of Origin 
HCT116 31.2 µM Colon 
MV4-11 53.5 µM Blood 
HeLa 39.1 µM Cervix 





Figure 2.4  Viability of HCT116 cells after 48 hrs of treatment with 
Andro(100 µM), P1(100 µM), P2(100 µM) and RA (100 µM) 
 
2.3.2 In situ proteome profiling 
 
To visualize the native cellular targets of Andro using fluorescence gel 
profiling (Figure 2.1), we treated live HCT116 cells with P1 or P2. The 
probe-labeled proteomes were reacted with Cy3 azide via click chemistry 
before being resolved on SDS-PAGE for fluorescence detection. As shown in 
Figure 2.5, in sharp contrast to the DMSO control, P2 labeled proteome 
yielded high fluorescence intensity bands, signifying that there were proteins 
interacted with P2. As expected, P1 labeled proteome showed rather weak 
intensity bands, possibly due to the instability of the ester linker. These 
observations supported our hypothesis and were consistent with a recent 
review, which postulated that the elimination of the β-hydroxy group of Andro 
might occur during the Andro alkylation (Gersch et al. 2012). Based on our 
results, the stronger labeling intensity of P2 in comparison to P1 suggests that 
the ester bond of P1 might be broken or hydrolyzed in the reaction, while the 
amide bond linkage in P2 is more stable (Gersch et al. 2012). Therefore, P2 




Figure 2.5  The in situ fluorescent labeling of HCT116 cells using P1 and P2 
(100 µM) together with a DMSO-treated negative control. Probe labeled 
proteomes were visualized by click conjugation to the Cy3 azide tag, SDS-gel 
separation, and fluorescent scanning.  
 
 
2.3.3 ICABPP and target identification 
 
We next performed ICABPP using P2 to identify specific cellular protein 
targets of Andro (Figure 2.1), which yielded 4 sets of Andro probe vs. control 
pull-down ratios (116/113; 117/113; 116/114; 117/114). A total of 291 proteins 
was successfully identified and quantified in our experiment (Figure 2.6). 
Outliers were identified using p-value >0.05 and 114/113 ratio >1.3 or <0.77. 
This resulted in 208 proteins being considered to be statistically reliable hits 
(Figure 2.6). The distribution of the enrichment ratios of these proteins were 
further presented as a coloured heat map in Figure 2.7. To reduce false positive 
targets, we chose a highly stringent ratio of 2 as the cut-off to differentiate 
 37 
 
specific (red) from non-specific (blue) binding targets. Meanwhile, proteins 
identified based on a single peptide are considered unreliable and were 
removed. Consequently, 75 proteins were regarded as the specific targets of 
Andro based on the above criteria (Figure 2.6). The complete list of the 75 





Figure 2.6  Venn diagram showing the total numbers of proteins quantified by 
ICABBP (green rectangle), statistically reliable proteins (blue) and specific 
binding targets (yellow). 
 
 
NF-κB p50, a known Andro target,(Bao et al. 2009; Wang et al. 2007; Xia 
et al. 2004) was found to be enriched 2.8 fold in Andro pull-down when 
compared to DMSO control, validating our approach. The subsequent pathway 
analysis suggested that Andro may exert its anti-cancer effects through 
multiple targets and pathways: more than 30 targets were involved in cancer 
cell death pathways; 15 hits were involved in cell migration and metastasis 
(Table 2.2 and Figure 2.8); 20 hits were related to inflammation and 10 to 
protein synthesis pathway (the respective pathway analyses are shown in 




Figure 2.7  Heat map of the enrichment ratio of potential Andro targets 
fulfilled the statistical requirement. The most enriched proteins are displayed in 
red, while the least enriched proteins are shown in blue. The color scale for 




Table 2.2  The potential protein targets related to cell migration and metastasis 




Figure 2.8  Ingenuity Pathway Analysis (IPA) revealing that Andro affects the 
cell migration and metastasis. All proteins shown in green nodes were identified 





Figure 2.9  Ingenuity Pathway Analysis (IPA) reveals Andro affecting cancer 
cell death and survival. All proteins shown in green nodes were identified as 
specific targets of Andro. 
 
 
Figure 2.10  Ingenuity Pathway Analysis (IPA) reveals Andro affecting 
inflammatory and immunological pathways. All proteins shown in green nodes 




Previously, many studies have been carried out to investigate the effect of 
Andro in inducing cancer cell death and anti-inflammatory effects(Zhou et al. 
2006; Zhou et al. 2010; Zhou et al. 2008; Jada et al. 2008). Interestingly, our 
targets and pathway analysis revealed the anti-metastatic effects of Andro, 
which has not been extensively studied thus far (Shi et al. 2009). Among these 
target proteins (Table 2.2) MYH9 and NPM1 have been reported to be 
associated with regional lymph nodes tumor metastasis (Liang et al. 2011; Y. 
Liu et al. 2012). YWHAZ has been reported to promote 
epithelial-mesenchymal transition in lung cancer (Chen et al. 2012). FLNA 
may promote metastasis by enhancing cell migration in melanoma (Gawecka 
et al. 2010). PFN1 is an actin-binding protein which was reported to be highly 
related to tumor cell metastasis (Hu et al. 2001). α/β-tubulin, known to be 
expressed at elevated levels in tumor cells, plays essential roles in 
maintenance of cellular shape and process of metastasis. HSPA1A and HSPD1 
have been reported to play an important role in tumorigenesis and metastasis 
of breast cancer (Barazi et al. 2002). Previous studies reported NF-κB p50 as a 
critical player in cancer metastasis by up-regulating MMP-9 and 
down-regulating anti-metastatic TIMPs and PAI 2 (Andela et al. 2000). Actin, 
one of the most abundant cytoskeleton proteins, participates in cancer 
metastasis by regulating cell motility (Yamaguchi & Condeelis 2007). The 
anti-metastatic effects of a variety of actin-binding agents have been 
extensively studied due to their therapeutic potential (Statsuk et al. 2005; 
Tannert et al. 2010; Kita et al. 2011; Quideau et al. 2011). In particular, we 
found NF-κB and -actin were the top two target proteins with the highest 
differential ratios among all the other targets involved in the metastatic 
pathway. Thus, these two proteins were chosen for further validation of 







2.3.4 Targets validation and functional analysis 
 
Direct interaction of Andro with both NF-κB and Actin were first 
validated by pull-down followed by Western blot (Figure 2.11). Recombinant 
NF-κB p50 protein was used for subsequent in vitro labeling experiments. The 
protein was incubated with different concentrations of P2 for 4 hrs with 
DMSO-treated p50 as the negative control (Figure 2.12). The labeling only 
occurred to the native p50 in the presence of P2. Heat denatured p50 could not 
be labeled, suggesting the interaction is specific and physiologically relevant. 
Competition assay by pre-treating p50 with 10-fold excess of Andro resulted 
in drastically diminished fluorescent signal, further confirming the specific 
binding between p50 and the drug. The presence of reducing agents DTT and 
BME dramatically reduced the labeling, indicating that the reaction site might 
be cysteine residues. Previous research has suggested Cys62 of p50 as the 
binding site of Andro (Xia et al. 2004). Our in vitro labeling result confirmed 
the important role of Cys62 of p50 in Andro binding, which upon mutation to 
Ala significantly diminished the labeling efficacy (Figure 2.12, lane 11).  
We further explored the exact modification site of Andro on p50 using 
MS/MS sequencing. The Andro-treated p50 protein, together with the 
untreated control, were digested with trypsin and analysed by MS/MS. The 
peptide YVCA*EGPSHGG-LPGASEK (Figure 2.13) was identified, in which 
Andro bound to the cysteine residue with the loss of one molecule of H2O 
(Figure 2.14) (Xia et al. 2004; Gersch et al. 2012). Based on above results, we 





Figure 2.11  Western-blot validation of pulled-down fractions of HCT116 by 






Figure 2.12  In vitro labeling of recombinant NF-κB p50 protein with P2: P50 
is concentration-dependently labeled by P2 only in its native form, Δ=heat 
denaturation control; DTT and β-mercaptoethanol (BME) co-treatment, 10-fold 
excess Andro pre-treatment reduce the labeling; Drastically reduced labeling of 
p50 mutant shows Cys62 is the critical amino acid for Andro labeling. 
Coo=Coomassie staining; Flu=fluorescence scanning image. 
 
 
To gain insight on how Andro alkylation inhibits DNA-binding activity of 
p50, a docking model was constructed. The thiol group of Cys62, which is 
located in the DNA-binding motif, is critical in DNA recognition of the p50 
subunit. As shown in Figure 2.15, the docking simulations presented a 
comprehensive model, in which Andro binds p50 at the active DNA-binding 
site through interaction with Cys62, the critical amino acid, thereby inhibiting 
transcription by blocking DNA binding of NF-κB. Our docking model thus 
provided further hint that the anti-cancer effects of Andro is at least in part 








Figure 2.13  The MS/MS spectra of the NF-κB p50 peptide containing Cys62. P50 was incubated without (top) and with (bottom) 
Andro for 4hrs, and digested by trypsin. CA*represents the Andro modified Cys. Fragment ions containing modified Cys are 

























Figure 2.15  Docking simulation model showing Andro binding to the NF-κB 
p50 subunit through the critical amino acid Cys62 and Arg57. a, c) Ribbon 






Previous studies showed that several small molecules can bind to actin by 
forming a covalent bond with Cys via similar Michael addition reactions 
(Statsuk et al. 2005; Aldini et al. 2007; Gayarre et al. 2006). To validate the 
interaction between actin and Andro, -actin in G-buffer and F-buffer were 
incubated with Andro, respectively. The results demonstrated that Andro 
selectively bound to polymerized F-actin (Figure 2.16). The binding site of 
Andro on actin was subsequently confirmed to be Cys272 by MS/MS, which 
was reported as a highly reactive cysteine due to its full solvent accessibility 




Figure 2.16  In vitro labeling of purified -actin protein using P2. G: actin in 
G-buffer; F: actin in F-buffer; Δ=heat denaturation prior to labeling. 
Coo=Coomassie staining, Flu=fluorescence scanning. 
 
 
Finally we verified the anti-metastatic potential of Andro using cell 
migration and invasion assays. HCT 116 cells were treated with RA and Andro 
at a non-cytotoxic concentration of 5µM for 30 hrs. The results showed that 
Andro can effectively suppress the migration and invasion of HCT116 cells 
(Figure 2.18). These results further supported our novel finding on the role of 
Andro in inhibiting tumor metastasis, thus broadening its therapeutic 





Figure 2.17  The MS/MS spectra of -actin peptide containing Cys272. Polymerized actin in F-buffer was incubated without (top) 
and with (bottom) Andro for 4hrs, and digested by chymotrypsin. CA* represents the Andro modified Cys. Fragment ions containing 






Figure 2.18  Inhibition of cancer cell migration and invasion by Andro. a) Cell 
migration and invasion assays of HCT116 cells treated with DMSO, RA (5 µM) 
and Andro (5 µM), respectively. Cells were seeded in inserts coated with either 
fibronectin or matrigel and allowed to migrate and invade towards FBS 
containing medium for 30 hrs before imaging and quantification. b) & c) 
Histogram showing significant differences in cell migration and cell invasion, 
respectively. (*** p-value<0.001)  
 
 
As actin plays an important role in cytokinesis, we further examined 
Andro’s effect on cell cycle using flow cytometry. Our data showed that 
HCT116 cells were arrested at G2/M phase upon Andro treatment in a 
time-dependent manner (Figure 2.19). We also analyzed the cell cycle using 
other cell lines including HeLa and HepG2. Significant cell cycle arrest was 




Figure 2.19  Flow cytometry cell cycle analysis of HCT116 cells treated with 






Figure 2.20  Cell cycle analysis of Andro-treated HeLa cells (a) and HepG2 







In conclusion, our results demonstrated that the ICABPP method, which 
combines clickable ABPP and iTRAQ, is a powerful approach to identify 
specific drug targets in live cells. In this study, a spectrum of specific targets 
of Andro was identified using this new method. In particular, we have 
identified the novel anti-metastasis potential of Andro through targets and 
pathway analysis, which have been validated through subsequent migration 
and invasion assays. To the best of our knowledge, this is the first report that 
systematically combines the iTRAQ-based quantitative proteomics with the 
clickable activity-based probe to profile specific drug targets in live cells. 
In practice, ICABPP method can be easily optimized and used in all kinds 
of affinity chromatography or ABPP-based target identification. The 
multiplexing property of the iTRAQ enables the precise and accurate 
quantitation of up to 8 samples simultaneously, allowing the inclusion of the 
biological replicates or drug competition of pull-down samples. Moreover, it 
can be used to study drug targets using tissue or body fluid samples in clinical 
research. We anticipate this ICABPP approach to be widely applied in drug 
development and optimization to refine the therapeutic potentials of drugs by 






  Chapter 3
 
Development of a novel method for quantification of 
autophagic protein degradation by AHA labeling 
 
3.1 Summary  
 
Autophagy is a cellular catabolic process that cellular components 
including protein aggregates and organelles are degraded via a 
lysosome-dependent pattern to sustain cellular metabolic homeostasis during 
nutrient or energy deprivation. Measuring the rate of proteolysis of long-lived 
proteins is a classical assay for measurement of autophagic flux. However, the 
traditional methods, like the radioisotope labeling assay, are technically 
tedious and with low sensitivity. In this chapter, we report a novel method for 
quantification of long-lived protein degradation based on L-azidohomoalanine 
(AHA) labeling in mouse embryonic fibroblasts (MEFs) and in human cancer 
cells. AHA is a surrogate for L-methionine, containing a bioorthogonal azide 
moiety. When added to cultured cells, AHA is incorporated into proteins 
during active protein synthesis. After a click reaction between an azide and an 
alkyne, the azide-containing proteins can be detected with an alkyne-tagged 
fluorescent dye, coupled with flow cytometry. Induction of autophagy by 
starvation or mTOR inhibitors was able to induce a significant reduction of the 
fluorescence intensity, consistent with other autophagic markers. Coincidently, 
inhibition of autophagy by pharmacological agents or by Atg deletion 
abolished the reduction of the fluorescence intensity. Comparing to the 
classical radio-isotopic pulse labeling method, we believe that our method is a 
sensitive, quantitative, no-radioactive and easy to perform, and can be applied 






Autophagy is an evolutionarily conserved self-digestive process in 
response to starvation or other stress conditions to sustain cellular homeostasis 
(Nakatogawa, Suzuki et al. 2009; Yang, Zhao et al. 2009). Autophagy plays 
crucial roles in development, innate immune defense, tumor suppression, and 
cell survival (Mizushima and Levine ; Levine and Kroemer 2008). During the 
induction of autophagy, portions of cytoplasmic materials, including 
macromolecules (such as stable, long-lived proteins) are engulfed into 
specialized double-membrane structures to form autophagosomes, which then 
fuse with lysosomes to degrade their cargos and regenerate nutrients 
(Mizushima 2007). Under normal growth conditions, autophagy is kept at a 
basal level to maintain turn-over of long-lived proteins and damaged 
organelles. Under starvation conditions, autophagy is induced to enhance the 
catabolic process to provide cells with additional internal nutrient supplies. 
This induction is largely due to inhibition of the mechanistic target of 
rapamycin (MTOR), the key negative regulator of autophagy through 
suppression of the ULK1 complex consisting of ULK1, FIP200 and Atg13 
(Mizushima ; Hosokawa, Hara et al. 2009). 
Among various assays developed to measure the autophagic flux, the 
classical method is determination of long-lived protein degradation by 
radioisotope labeling assay. This method firstly pulse-labeled the cellular 
proteins by incorporation of radioactive amino acids [14C]-leucine or 
[14C]-valine (Ogier-Denis, Houri et al. 1996; Roberts and Deretic 2008), and 
then followed by a long cold-chase to chase out short-lived proteins. Next, the 
time-dependent release of acid-soluble radioactivity from the degraded 
proteins in intact cells is measured. Although the radioisotope-based 
autophagic proteolysis of long-lived proteins assay is considered to be a gold 
standard in measuring autophagic proteolysis, this method is technically 
tedious, insensitive, and inconvenient (with requirement of radioactive 
containment). Though Doherty et al. (Doherty, Hammond et al. 2009) updated 
this method by using dynamic stable isotope labeling with amino acids in cell 
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culture (SILAC), coupled with quantitative mass spectrometry, the lengthy and 
laborious process would limit its wide application. Thus, a radioactive-free 
method which can quickly and specifically quantify the long-lived protein 
degradation is highly demanded.  
Recently, new techniques for labeling a variety of molecules based on the 
principle of bio-orthogonal metabolic labeling have been developed (Best 
2009), such as bio-orthogonal noncanonical amino acid tagging (BONCAT) 
and fluorescent noncanonical amino acid tagging (FUNCAT) which have been 
used to tag and identify or visualize newly synthesized proteins (Dieterich, 
Link et al. 2006). Such methods are particularly useful when direct labeling or 
the use of antibodies is not applicable or efficient. L-azidohomoalanine (AHA), 
an amino acid analog of methionine containing an azide moiety, can be 
incorporated into de novo protein synthesis and can be readily detected by a 
chemoselective ligation between an azide and alkyne-bearing tags (Dieterich, 
Link et al. 2006). AHA has been successfully used for detection of nascent 
protein synthesis, in combination with proteomic techniques, including gels, 
blots, and mass spectrometry (Dieterich, Link et al. 2006; Dieterich, Lee et al. 
2007).  
Here we report a novel method which combines the pulse-AHA labeling, 
click-chemistry tagging and flow cytometry detection to quantitatively 
measure the long-lived protein degradation during autophagy. We tested this 
method in both normal and cancer cells, under various autophagy induction 
and inhibition conditions. This assay provides a fast, sensitive, and 
non-radioactive method for quantification of autophagic proteolysis, 
applicable to in vitro cell culture systems. This method could also be adapted 
for high-throughput screening of novel pharmacological agents that enhance 






3.3.1 AHA labeling and detection of AHA by click reaction 
 
As shown in Figure 3.1A, AHA is an effective surrogate for methionine, 
an essential amino acid, which does not require any further manipulations to 
be incorporated as a substrate by the methionyl-tRNA synthetase into the 
proteins during de novo protein synthesis.  
The amount of AHA incorporated into the protein can be detected using 
the “click” reaction between azide and alkyne, and a broad range of 
functionally and biochemically diverse proteins that incorporated with AHA 
can be specifically tagged with a corresponding alkyne-containing dye or 
hapten, and subject to subsequent analysis by flow cytometry, imaging or 
standard biochemistry techniques such as gel electrophoresis (Figure 3.1B).   
Based on the AHA labeling and click reaction as described above, we here 
developed a protocol for quantification the long-lived protein degradation in 
autophagy, as shown in Figure 3.2. Firstly, cells are incubated with AHA to 
allow incorporation of AHA into proteins, followed by a period of cold-chase 
to get rid of the short-lived proteins. Subsequently cells were subject to 
modulation of autophagy (induction and/or suppression). Finally, cells were 
harvested, fixed and permeabilized followed by a click reaction with TAMRA 
alkyne. Using flow cytometry, the AHA signal intensity will be measured 
which is inversely correlated to the amount of long-lived proteins left after 
autophagy.  
3.3.2 Optimization of AHA labeling  
 
Growth medium, cell density, cell type variations and other factors may 
influence the AHA labeling capacity. For initial experiments, we optimized the 
labeling and reaction conditions in terms of AHA concentration and incubation 
time. Mouse embryonic fibroblasts (MEFs) were plated at desired density 



















Figure 3.1  AHA labeling of newly synthesized proteins. AHA labeling of 
newly synthesized proteins. (A) Structure of azidohomoalanine (AHA), an 
analog of methionine containing an azide moiety. (B) Click azide/alkyne 
reaction. The azide and alkyne moieties are interchangeable, where the 




medium was removed and washed with PBS twice, cells were then cultured in 
L-methionine-free DMEM with different dosages of AHA (Note that cells 
should be labeled in methionine-free medium, as methionine is the preferred 
substrate for methionyl tRNA transferase (Kiick, Saxon et al. 2002)).  
Firstly, we tested a range of AHA concentrations to determine the optimal 
concentration for our cell type and experimental conditions. As shown in 
Figure 3.3A, we observed a dose-dependent increase of the AHA signal 
intensity up to 100 μM, while the signal reached the plateau by the 
concentration of 25 μM. Next, we tested the time-course of AHA labeling by 

























Figure 3.2  Workflow for AHA labeling-based quantitative analysis of protein 
degradation. The bioorthogonal noncanonical amino acid tagging (BONCAT) 
strategy for labeling, detection and identification of newly synthesized proteins. 
Cells are incubated with AHA to allow protein synthesis. After incubation, cells 
were harvested, fixed and permeabilized. Nascent protein synthesis was 
detected following a click reaction with TAMRA alkyne and analysis was 





Figure 3.3  Dose- and time-dependent metabolic labeling of AHA in MEFs. 
(A) MEFs were treated in L-methionine-free meidum with different dosages of 
AHA for 18 h. Cell were then transferred into common medium with 10x 
L-methionine (2 mM) for 2 h. Finally, the cells were harvested, fixed and 
permeabilized for the click reaction, as described in Materials and Methods. (B) 
as in (A), MEFs were labeled with 25 μM AHA at different time points (6, 12, 
18 and 24 h) and cellular fluorescence intensity was analysed as described.  
 
 
increase of the AHA signal intensity (Figure 3.3B). We further confirmed the 
AHA label by examining the fluorescence intensity in SDS-PAGE. As shown 
in Figure 3.4, only the cells labeled with AHA were detected with fluorescence. 
The Coomassie staining was used to show the equal loading of the protein 
samples.  
To determine the specificity of AHA incorporation into newly synthesized 
proteins, we added a protein synthesis inhibitors cycloheximide (CHX) into 
the labeling medium along with AHA. As shown in Figure 3.4, the presence of 
CHX completely abolished the fluorescence signal in cells with AHA labeling, 























Figure 3.4  Visualization of AHA-labeled proteins. MEFs were labeled with 
AHA (25 μM x 18 h) and then the cells were harvested for click tagging and 
in-gel fluorescence scanning. Coomassie staining was used to show the equal 
protein loading. Cycloheximide (CHX, 10 μg/ml) was added to inhibit de novo 
protein synthesis and the cells cultured in common medium were used as the 
negative control.  
 
 
It has been reported that the metabolic labeling of mammalian cell with 
AHA did not alter global protein synthesis rates or protein degradation 
(Dieterich, Link et al. 2006). As shown in Figure 3.5, labeling with different 
concentrations of AHA for 18 hours did not change the cell morphology, 










Figure 3.5  Morphological changes of MEFs with different dosages of AHA 
labeling were examined and photographed with an inverted microscope (Scale 
bar 200 μM). 
 
3.3.3 Autophagy-mediated protein degradation detection by 
AHA fluorescence 
 
We next tested the changes of AHA fluorescence intensity in MEFs 
undergoing autophagy induced by a well-established autophagy inducer 
starvation (culturing cells in amino acid-free medium) (Munafo and Colombo 
2002). As shown in the left panel of Figure 3.6A, starvation for 3 h caused a 
20% reduction in the AHA signal intensity, and the magnitude of reduction is 
agreeable to a previous report detected by the degradation of mitochondrial 
(Kawai, Takano et al. 2006). Starvation for a longer period of time (6 h) 
induced a further reduction in cell fluorescence intensity, with about 70% of 






























Figure 3.6 Autophagy induction increased long-lived protein degradation. 
Cells were first labeled with AHA as described above, and then the cells were 
cultured in starvation or treated with mTOR inhibitors (rapamycin×1 μM, 
pp242×1 μM or Torin1×1 μM) for 3 h (A). Left panel for MEFs; right panel for 
HepG2 cells. Data for the relative signal intensity were expressed as the ratio of 
treated cells to control cells, as mean ± SD from three independent experiments, 
* p < 0.05, ** p < 0.01, Student’s t-test. (B) MEFs were treated with starvation 






In addition to starvation, we also measured autophagic protein 
degradation induced by different mTOR inhibitors, including rapamycin (an 
allosteric mTOR inhibitor), and pp242 and Torin 1 (two catalytic mTOR 
inhibitors) (Huo, Iadevaia et al.). As shown in the left panel of Figure 3.6A, 
both pp242 and Torin 1 were found to be as effective as starvation in causing 
protein degradation, and also in a similar time-dependent manner. Interestingly, 
rapamycin failed to induce a significant decrease of AHA fluorescence 
intensity with a shorter treatment duration (3 h) and the degree of autophagic 
proteolysis by rapamycin was weaker compared to other treatments, which is 
consistent with the previous study that rapamycin was found to be a relatively 
weaker autophagy inducer (Kawai, Takano et al. 2006).  
Similar results were also obtained in HepG2 cells (Figure 3.6A, right 
panel), although the average AHA fluorescence intensity reduction was about 
10% in cells under starvation and mTOR inhibitors (pp242 and Torin 1) for 3 
h, which is relatively weaker when compared to MEFs, suggesting that cell 
type variations may influence autophagic proteolysis rate measured by this 
assay. 
To further evaluate the efficiency of autophagy induction, we also 
performed western blotting to determine changes of mTOR activity and 
autophagy markers. As shown in Figure 3.7, starvation and mTOR inhibitors, 
such as rapamycin, pp242 and Torin 1, increase LC3-II level and decrease p62 
level, indicating a higher autophagy level. Meanwhile, the effectiveness of 
starvation and mTOR inhibitors were verified with the phosphorylation 
blockage of S6 (S235/236) seen in MEFs and HepG2 cells. Different from 
other treatments, rapamycin was largely ineffective on phospho-4E-BP1 
(Thr37/46). Such observations are consistent with the current understanding 
that rapamycin is an allosteric inhibitor of mTOR and only suppresses part of 
mTOR function, while both pp242 and torin1 are catalytic inhibitors that are 




Figure 3.7  Western confirmations of Starvation and chemical induced 
Autophagy in MEFs. MEFs were treated as in Figure 3.6A and cell lysates were 
prepared for western blotting. β-actin was used as the loading control. (left 
panel: 3 hrs treatment; right panel: 6 hrs treatment) 
 
3.3.4 Autophagy inhibitors reversed the reduction of AHA 
fluorescence  
 
To verify this method of autophagic proteolysis, we utilized 
pharmacological inhibitors of autophagy to observe the changes of AHA 
fluorescence. Wortmannin, a phosphatidylinositol-3-kinase (PI3K) inhibitor, 
can specifically inhibit macroautophagy (Kovacs, Rez et al. 2000). 
Bafilomycin A1, a selective inhibitor of the lysosomal V-ATPase, is able to 
block the fusion between autophagosome and lysosome (Yoshimori, 
Yamamoto et al. 1991). In cells under starvation for 3 h (Figure 3.8A, left 
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panel for MEFs and right panel for HepG2 cells), both inhibitors were able to 
significantly reverse the reduction of AHA fluorescence intensity, although 
wortmannin appeared to be more effective than bafilomycin A1.  
We also tested the effects of these two autophagy inhibitors on autophagy 
induction by pp242. As shown in Figure 3.8B (left panel for MEFs and right 
panel for HepG2 cells), both inhibitors were also able to abolish the reduction 
of AHA fluorescence.  
 
 
Figure 3.8  Autophagy inhibition blocked long-lived protein degradation. 
Cells were labeled with AHA as described earlier and then cultured in common 
medium with 10× L-methionine (2 mM) for 2 h in the presence or absence of 
autophagy inhibitors (Wort×100 nM or BAF×50 nM), followed by either 
starvation (A) or  pp242×1 μM (B) for 3 h, in the presence or absence of 
autophagy inhibitors. Left panel for MEFs; right panel for HepG2 cells. Data 
for the relative signal intensity were expressed as the ratio of treated cells to 
control cells, as mean ± SD from three independent experiments, * p < 0.05, ** 




Meanwhile, we performed western blotting to confirm the effectiveness of 
wortmannin and bafilomycin A1 to block autophagy induced by starvation and 
pp242. In MEFs (Figure 3.9) and HepG2 cells (Figure 3.10), starvation and 
pp242 increased the autophagic flux, accompanied with a further increase in 
LC3-II level and decrease in p62 level when bafilomycin A1 was added; 
whereas wortmannin led to a further decrease in LC3-II level and increase in 
p62 level. In addition, the effectiveness of starvation and pp242 were verified 
with the phosphorylation blockage of S6 (S235/236) and 4E-BP1 (Thr37/46). 
Thus it further supported that the degradation of protein by autophagy can be 




Figure 3.9  Western confirmations of Autophagy inhibition by Bafilomycin 
and Wortmannin in MEFs. MEFs were treated as described in Figure 3.8A and 
Figure 3.8B. Cells were then harvested and protein from cell lysates was 





Figure 3.10  Western confirmations of Autophagy inhibition by Bafilomycin 
and Wortmannin in HepG2. HepG2 cells were treated as described in Figure 
3.8A and Figure 3.8B. Cells were then harvested and protein from cell lysates 
was analyzed with western blotting. β-actin served as a loading control. 
 
 
3.3.5 Autophagy deficiency prevented protein degradation 
measured by AHA labeling  
 
To further examine the usefulness of this assay in measuring autophagic 
proteolysis, here we measured the changes of AHA fluorescence in cells 
deficiency of key autophagy-related genes including Atg5 and Atg7. We 
observed only minor degree of protein degradation in both Atg5 KO MEFs 
and Atg7 KO MEFs under various autophagy inducers, in comparison to their 
respective wild-type counterparts (Figure 3.11A and 5B, respectively). 
Interestingly, we also observed some reduction of AHA fluorescence intensity 
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in the Atg5 or Atg7 KO MEFs, especially in Atg7 KO MEFs under starvation, 
suggesting the possibility of autophagy-independent protein degradation in the 
treated cells, such as proteasome-mediated protein degradation (Vabulas and 
Hartl 2005). Meanwhile, western blotting analysis was performed to determine 
the identity of the cells and autophagy markers induced by starvation or 
mTOR inhibitors (Figure 3.12A and B). Autophagy inducers increased LC3-II 
level and decreased p62 level in wild type MEFs, but not in autophagy 
deficiency cells, although their suppressive effects on mTORC1 activity were 




Figure 3.11  Defective autophagy impaired long-lived protein degradation. 
Atg5 WT and KO MEFs (A) and Atg7 WT and KO MEFs (B) were labeled 
with AHA and then treated with starvation or mTOR inhibitors for 3 h, as 
described in Figure 3.6A. Data for the relative signal intensity were expressed 
as the ratio of treated cells to control cells, as mean ± SD from three 




Figure 3.12  Western confirmations of Autophagy inhibition and deficiency in 
Atg WT and KO MEFs. Atg5 WT and KO MEFs (A) and Atg7 WT and KO 
MEFs (B) were treated as described in panel A and B, and then harvested and 
proteins from cell lysates were analyzed with western blotting. β-actin served as 





At present, measurement of “autophagic flux” in the autophagy study is 
still technically challenging (Klionsky, Abdalla et al.). Several assays have 
been described and commonly used, including (i) turnover of autophagy 
markers such as LC3-II and GFP-LC3 puncta in the presence of lysosomal 
inhibitors such as chloroquine (CQ); (ii) changes of p62/sequestosome protein 
level, and (iii) use of the GFP and RFP tandemly tagged LC3 (tfLC3), and (iv) 
quantification of autophagic proteolysis by radioisotope labeling. In the 
present study, we described a novel assay to quantify long-lived protein 
degradation in autophagy using AHA labeling coupled with flow cytometry. 
Comparing to the classical radioisotope labeling method, this assay is 
non-radioactive, sensitive, specific, quantitative, relatively easy to perform and 
versatile in the mammalian cell culture systems, and thus offers a good tool to 
many laboratories in the field of autophagy research.   
Recently, the BONCAT technique has been used to identify newly 
synthesized proteins in mammalian cells through the co-translational 
introduction of azide groups into proteins and the chemoselective tagging of 
azide-labeled proteins with an alkyne affinity tag (Dieterich, Link et al. 2006). 
Based upon this technique, the metabolic labeling of AHA into newly 
synthesized proteins has been widely used in mammalian cells (Dieterich, 
Link et al. 2006), primary neuronal cells and organotypic brain slice cultures 
(Dieterich, Hodas et al.) and larval zebrafish (Hinz, Dieterich et al.). Labeling 
with AHA is similar to the traditional metabolic labeling with radioactive 
amino acids (35S-labeled methionine or cysteine). Unlike other labels, the 
azide is small enough to be tagged with biomolecules (such as sugars and 
amino acids) that are acceptable as substrates for the enzymes to incorporate 
them into proteins. However, the application of AHA labeling in measuring 
protein degradation has not yet been explored at present. In this study, we 
established a novel technique for the study of autophagic proteolysis. In cells 
induced by starvation or mTOR inhibitors to activate autophagy, there was a 
significant reduction of the AHA signal intensity (Figure 3.6A and 3B). 
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Consistently, suppression of autophagy by pharmacological inhibitors 
effectively prevented the reduction of AHA signal intensity (Figure 3.8A and 
4B). More importantly, no obvious reduction of AHA signal was found in 
MEFs with deletion of Atg5 or Atg7 (Figure 3.11A and 4B). Therefore, it is 
thus believed that the reduction of the AHA signal intensity specifically 
measures the protein degradation due to autophagy.    
When compared to radioisotope labeling in the measurement of 
autophagic proteolysis, there are a few advantages of AHA labeling. Firstly, 
AHA labeling is much simpler and easier to perform, non-toxic, and does not 
affect global rates of protein synthesis or degradation (Dieterich, Link et al. 
2006). In contrast, radioisotope labeling is more laborious and requires a high 
level of technical expertise to operate the instruments and conduct experiments. 
Moreover, radioisotope labeling diminishes half-lives of proteins and alters 
metabolic stability (Yewdell, Lacsina et al.). For example, commercially 
available radioisotope-labeled amino acids from bacteria contain bacterial 
components which may influence protein stabilities through triggering cellular 
innate immune receptors (Lelouard, Gatti et al. 2002). 
Secondly, in AHA-labeled cells, the cellular fluorescence intensity reflects 
the amount of remaining proteins (Dieterich, Link et al. 2006), including both 
cytosolic and membrane proteins, and thus exclude factors related to free AHA 
release, implicating that this is a more accurate and reliable method. In 
contrast, in radioisotope-labeled cells, only the acid-soluble radioactivity 
released into the medium from the labeled proteins in intact cells is measured 
(Yewdell, Lacsina et al. ; Ogier-Denis, Houri et al. 1996; Roberts and Deretic 
2008). Therefore, the latter method seems less accurate and sensitive 
compared to our methodology.  
There are several important technical issues in establishing this assay. 
Firstly, AHA labeling has to be performed in methionine-free medium with 
dialysed fetal bovine serum (FBS, elimination of L-methionine from other 
sources), because the incorporation efficiency of AHA is much lower than 
natural methionine (Kiick, Saxon et al. 2002). Therefore, theoretically the 
presence of endogenous methionine inside the cells may adversely affect AHA 
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labeling. Secondly, AHA labeling is unable to pick up proteins without 
methionine. Based on the estimation that such proteins only constitute 1.02% 
of all entries in a human protein database and that 5.08% of the human 
proteome possess only a single, N-terminal methionine that may be removed 
by post-translational modification (Dieterich, Link et al. 2006), AHA labeling 
is applicable to about 94% of the mammalian proteomes. Lastly, we 
acknowledge that this assay is unable to measure the basal proteolysis rate in 
the control cells, as it only determines the extent of protein degradation in the 
treated cells in comparison to the control cells. However, we believe that this 
limitation should not impair the value of this assay as a tool in autophagy 
study. 
 
3.5 Conclusion and future directions 
 
In summary, we have successfully developed a novel method by using 
AHA labeling as a simple, sensitive, specific and quantitative tool to measure 
autophagic protein degradation. This assay is mainly applicable to cell culture 
systems in vitro and it could be easily adapted for high throughput screening 
of autophagy modulators.  
In future, we will focus on individual protein degradation rate and reveal 
inherent protein intracellular stability. Following AHA labeling, subcellular 
fractionation and immunopurification of protein complexes can be prepared 
and mass spectrometry will be performed to assess the temporal and spatial 
dynamics of certain subcellular compartments, organelles and protein-protein 
interaction networks. According to the previous studies, Mary K. Doherty et al 
performed dynamic SILAC, stable isotope labeling by amino acids in cell 
culture for mass spectrometry (MS)-based quantitative proteomics, and 
profiled the intracellular degradation rate of almost 600 proteins from human 
A549 adenocarcinoma cells( Mary K. Doherty et al, 2009). In contrast to 
SILAC, Hsueh-Chi Sherry Yen developed a highly parallel multiplexing 
strategy, called global protein stability profiling (GPSP) by coupling flow 
cytometry with microarray technology, to monitor global protein turnover and 
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examine the stability of individual proteins. In HEK293T cells, they measured 
the stability of ~8000 human proteins and identified proteosome substrates 
(Hsueh-Chi Sherry Yen, 2008). However, cross-correlating the SILAC and 
GPSP data sets showed a plotted 339 shared gene products against each other 
(Yewdell JW, et.al. 2011). Surprisingly, no significant correlation between the 
common members of the two data sets was observed. Therefore, in our next 
step, we will conduct AHA labeling in combination with mass spectrometry to 
investigate global protein turnover profiles in autophagy and may reveal the 













All chemicals and solvent used in this dissertation were purchased from 
commercial suppliers and used without further purification unless otherwise 
stated. The andro probes were designed by the dissertation author and 
synthesised by commercial company. 
 
4.2 Materials and methods of Chapter 2 
 
4.2.1 General Information (Synthesis) 
 
All chemicals and solvents were obtained from commercial sources and 
used without purification. Andrographolide (Andro), PPTS, 
2,2-Dimethoxy-propane, hex-5-ynoic acid, Pd/C and NaBH4 used in synthesis 
were purchased from Alfa (China). All reactions requiring anhydrous 
conditions were carried out under an argon or nitrogen atmosphere in flame 
dried glassware. HPLC grade solvents were used. Experiments were 
monitored by thin layer chromatography (TLC) or liquid chromatography 
mass spectrometry (LC-MS).  
1HNMR and 13C NMR spectra were recorded on a Bruker AVANCE III 
300 and 500 MHz spectrometer. Chemical shifts are reported in δ ppm, and J 
values are reported in Hz. Liquid chromatography mass spectra were obtained 
using a Shimadzu LC-IT-TOF spectrometer or a Shimadzu LC-ESI 
spectrometer. 0.1% TFA/H2O and 0.1% TFA/acetonitrile were used as eluents 








Scheme 4.1  The synthetic scheme for RA. 
 
Andro (50 mg, 0.14 mmol) was dissolved in methanol (20 mL). Then 
NaBH4 (6 mg, 0.14 mmol) was added under Argon. After addition, the 
reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was 
quenched by addition of water (10 mL) and EA. (100 mL). The organic phase 
was separated from the aqueous phase, washed with brine (20 mL), dried with 
Na2SO4, and then concentrated to obtain the crude product, which was purified 
with Prep-TLC (silica gel, eluent : dichloromethane/methanol=15 : 1) to 
obtain RA (10 mg) as white solid. Yield: (20%). 1H NMR (500 MHz, 
DMSO-d6), δ 5.39 (d, J = 4.0 Hz, 1H), 5.05 (d, J = 4.5 Hz, 1H), 4.78 (s, 1H), 
4.74 (s, 1H), 4.36 (m, 1H), 4.24 (dd, J1 = 3.0 Hz, J2 = 10.0 Hz, 1H), 4.12 (d, J 
= 5.0 Hz, 1H), 4.05 (d, J = 10.0 Hz, 1H), 3.84 (d, J = 9.0 Hz, 1H), 3.24 (m, 
2H), 2.32 (m, 1H), 1.91 (m, 1H), 1.58-1.73 (m, 6H), 1.42-1.50 (m, 2H), 1.32 
(m, 2H), 1.07 (s, 3H), 0.60 (s, 3H); 13C NMR (500 MHz, DMSO-d6), δ 178.8, 
148.0, 107.4, 79.0, 75.1, 68.0, 63.1, 56.1, 56.0, 45.0, 42.7, 40.9, 39.2, 38.4, 
37.0, 28.4, 24.5, 23.5, 22.7, 21.5, 15.3. LC-MS (IT-TOF) calcd for [M+H]+: 








4.2.3 Synthesis of the clickable probe P1 
 
Scheme 4.2  The synthetic scheme for P1. 
 
 
To a suspension of Andro (1.4 g, 4.0 mmol) and 2, 2-Dimethoxy-propane 
(2.08 g, 20.0 mmol) in toluene (50 mL), PPTS (0.1 g, cat.) and DMSO (2 mL) 
were added. The mixture was heated to reflux for 2 hrs. After the reaction 
mixture was cooled down, water (100 mL) and EA (150 mL) were added. The 
organic phase was separated, washed with brine (50 mL), dried with NaSO4, 
and then concentrated and purified by column chromatography (EtOAc: 
PE=1:10-50% EtOAc) to yield 1.3 g (83%) of the product 1 as a white solid. 
LC-MS (IT-TOF) calcd for [2M+H]+: 781.49, Found: 781.10; [2M+Na]+: 




To a solution of compound 1 (200 mg, 0.51 mmol) in DCM (50 mL), Et3N 
(103 mg, 1.02 mmol) was added at 0 °C under N2. Then compound 2 (100 mg, 
0.77 mmol) was added dropwise at 0 °C, The mixture was stirred at ambient 
temperature overnight by mechanical agitation. Then water (50 mL) was 
added, and the organic phase was separated and washed with brine (50 mL), 
dried with NaSO4, and then concentrated and purified by column 
chromatography (EtOAc: PE=1:20-40% EtOAc) to yield 100mg (40%) of the 
product 3 as a white solid. LC-MS (IT-TOF) calcd for [M+H]+: 485.29, Found: 
485.10.  
 
Compound 3 (50mg, 0.10 mmol) was dissolved in AcOH: H2O = 7:3 (5 
mL) at ambient temperature. The mixture was stirred for 30 min. Then pH was 
adjusted to 6 by NaHCO3. The desired aqueous solution was extracted with 
EA (50 mL × 3), the organic phase was washed with brine (50 mL), dried with 
Na2SO4, and then concentrated and purified by column chromatography 
(EtOAc: PE=1:10-100% EtOAc) to yield 20 mg (45%) of the product P1 as 
colorless oil. 1H NMR (300 MHz, CDCl3), δ 7.01 (dd, J= 6.9, 5.3 Hz, 1H), 
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5.92-5.94(d, J= 6.0 Hz, 1H), 4.88 (s, 1H), 4.53-4.59 (dd, J= 11.2, 6.1Hz, 1H), 
4.49 (s, 1H), 4.16-4.26 (m, 2H), 3.49 (m, 1H), 3.33 (d, J= 11.3 Hz, 1H). 2.53 (t, 
J= 7.4 Hz, 2H), 2.26-2.44 (m, 7H), 1.99 (t, J= 2.6 Hz, 2H), 1.71-1.91 (m, 6H), 
1.26 (s, 6H), 0.67 (s, 3H); 13C NMR (500 MHz, DMSO-d6) δ 173.7, 171.1, 
151.3, 148.8, 125.5, 108.9, 80.7, 73.1, 70.5, 69.2, 64.9, 57.1, 56.2, 43.6, 39.9, 
38.9, 38.1, 33.4, 29.0, 26.4, 25.2, 24.8, 23.4, 18.4, 15.6; LC-MS (IT-TOF) 




4.2.4 Synthesis of P2 
 




To a suspension of Andro (1.4 g, 4.0 mmol) and 2, 2-Dimethoxy-propane 
(2.08 g, 20.0 mmol) in toluene (50 mL), PPTS (0.1 g, cat.) and DMSO (2 mL) 
were added. The mixture was heated to reflux for 2 hrs. After the reaction 
mixture was cooled down, water (100 mL) and EA (150 mL) were added, and 
the organic phase was separated, washed with brine (50 mL), dried with 
NaSO4. And then concentrated and purified by column chromatography 
(EtOAc: PE=1:10-50% EtOAc) to yield 1.3 g (83%) of the product 1 as a 
white solid. LC-MS (IT-TOF) calcd for [2M+H]+: 781.49, Found: 781.10; 




Compound 1 (100 mg, 0.26 mmol, 1 equiv) was dissolved in dry CH2Cl2 
(5 mL), and the mixture was cooled to 0 °C. TEA (31 mg, 0.31 mmol, 1.2 
equiv) was added. MsCl (35 mg, 0.31 mmol, 1.2 equiv) was added dropwise, 
and the mixture was warmed to room temperature and allowed to stir for 30 
min. Upon consumption of starting material, the solvent was evaporated and 




To a solution of crude 4 in DMF (5 mL), NH3/C2H5OH (2 mL) was added 
at 0 °C, followed by a catalytic amount of cesium carbonate (10 mg), and the 
reaction was stirred at 0 °C for 0.5 h. Then the reaction was quenched with 
water (10 mL), and the aqueous phase was extracted with EA (10 mL), dried 
and concentrated. The residue was purified by silica gel column 
chromatography with EA to DCM: CH3OH=10:1 to obtain the compound 5 as 
white solid (30%). The configuration at C14 was partially reverted during this 
step, which made compound 5 a mixture of two isomers. The ratio of the two 
isomers was 1:0.8 as calculated in the NMR spectrum of P2. LC-MS (IT-TOF) 




To a solution of compound 5 (100 mg, 0.26 mmol) in DCM (10 mL), 
HATU (148 mg, 0.39 mmol), TEA (79 mg, 0.78 mmol) and hex-5-ynoic acid 
(30 mg, 0.39 mmol) were added. The mixture was stirred at RT for 2 hrs, and 
subsequently washed with water followed by brine, dried and concentrated, 
and the residue was purified by column chromatography with 
CH2Cl2:CH3OH=30:1 to obtain the compound 6 (55%) as a light yellow solid. 
LC-MS (IT-TOF) calcd for [M+H]+: 484.31, Found: 484.30. 
 
  
Compound 6 (50mg, 0.10 mmol) was dissolved in AcOH: H2O = 7:3 (5 
mL) at ambient temperature. The mixture was stirred for 30 min. Then pH was 
adjusted to 6 by NaHCO3. The desired aqueous solution was extracted with 
EA (50 mL × 3), and the organic phase was washed with brine (50 mL) and 
dried with Na2SO4. The organic phase was then concentrated and purified by 
column chromatography (CH3OH: DCM=1 : 30) to obtain 20 mg (45%) of the 
product P2 as white solid. 1H NMR (300 MHz, CD3OD), δ 7.46 (m, 0.44H), 
7.40 (m, 0.55H), 4.74-4.99 (m, 8H), 4.06-4.11 (m, 1H), 3.33-3.43 (m, 1H), 
2.14-2.46 (m,6H), 1.93-2.00 (m, 1H), 1.75-1.89 (m, 7H), 1.52-1.65 (m, 1H), 
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1.18-1.21 (m, 3H), 0.69 (s, 3H); 13C NMR (300 MHz, CD3OD) δ 174.7, 174.6, 
174.5, 174.3, 150.1, 148.6, 148.0, 147.6, 136.0, 133.8, 108.3, 107.9, 84.1, 80.8, 
80.7, 72.0, 70.5, 70.2, 64.9, 56.7, 56.4, 54.0, 53.8, 46.6, 45.9, 43.7, 43.6, 40.2, 
39.7, 39.5, 39.3, 38.1, 37.9, 35.6, 35.5, 29.2, 29.1, 29.0, 28.9, 25.9, 25.8, 25.4, 
23.4, 18.7, 18.6, 16.0, 15.7;  LC-MS (IT-TOF) calcd for [M+H]+: 444.27, 
Found: 444.30. 
 
4.2.5 Materials and Reagents (Biology experiments) 
Andrographolide (98%), Tris [(1-benzyl-1H-1,2,3-triazol-4-yl) 
methyl]amine(TBTA), Tris (2-carboxyethyl) phosphine (TCEP), streptavidin 
beads, acetonitrile (ACN), Trifluoroacetic acid (TFA), urea, dithiothreitol 
(DTT), phosphoric acid, and iodoacetamide (IAA) were purchased from 
Sigma-Aldrich. Antibody against NF-B p50 (SC-7178) was from Santa Cruz 
Biotechnology, Inc. Antibody against actin (1:4000) was from BD 
Transduction Laboratories. Migration assay and matrigel invasion assay 
chamber were purchased from BD Biosciences, San Jose, CA. Cy3-Azide 
(CLK-CCA-9294-1) and biotin-Azide were from Jena Bioscience, Inc. -actin 
from human platelet (>99% pure) was obtained from Cytoskeleton, Inc. 
Sequencing grade trypsin was obtained from Promega. Chymotrypsin, 
protease and phosphatase inhibitors cocktail were purchased from Roche. 
Ultrapure water used for all experiments was purified with an ELGA water 
system. Unless otherwise indicated, all the other reagents used for the 
biochemical methods were purchased from Sigma-Aldrich. 
 
4.2.6 Cell Culture 
HCT116, HepG2, HeLa and MV4-11 were purchased from ATCC 
(Manassas, VA). HCT116 was maintained in modified McCoy’s 5A medium 
with L-glutamine (Sigma, St. Louis, MO), supplemented with 10% fetal 
bovine serum (Invitrogen, Carlsbad, CA) and 1x antibiotic/antimycotic 
(Invitrogen, Carlsbad, CA) at 37oC in 5% (v/v) CO2. HepG2 and HeLa cell 
lines were cultured in Dulbecco’s Modified Eagle Medium (Sigma, St. Louis, 
MO) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) 
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and 1x antibiotic/antimycotic (Invitrogen, Carlsbad, CA). MV4-11 cell line 
was cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% 
fetal bovine serum and 1x antibiotic/antimycotic. Cells were maintained at 37 Ԩ 
in a humidified incubator supplemented with 5% CO2. 
 
4.2.7 Inhibition of Cancer Cell Proliferation  
HCT116, HeLa and HepG2 Cell Lines: 20,000 cells was seeded into 96 
well plate and allowed to attach for 24 hrs. Cells were then treated with Andro 
at various concentrations for 48hrs. At the end of the treatment, media was 
removed and the wells were washed once with PBS. The cells were then 
stained with 0.5% crystal violet in 20% methanol for 10 min. Excess crystal 
violet was washed off with PBS and the wells were allowed to dry. 
Solubilization was done using 1% SDS for 30 min and the absorbance 
measured at 550nm. 
MV4-11 Cell Lines: Cells were treated with increasing concentration of 
Andro for 48 hrs. Following the intended treatment, the cells were centrifuged 
and resuspended in 2 mL medium. A volume of cell suspension containing 
1x105 cells was centrifuged into a pellet. After dislodging the pellet, the 
samples were added with 10 μL of 50 μg/mL propidium iodide (PI) and 
subjected to flow cytometric analysis using the Beckman Counter (EPICS-Xl 
MCL). 
 
4.2.8 In situ Fluorescence Labeling Experiments 
HCT116 cells were grown to 80-90% confluence in 6-well plates. After 
the media was removed, cells were washed twice with PBS. P1 or P2 (100 μM) 
in 2 ml medium with a final DMSO concentration of 1% was added and cells 
were incubated for 4 hrs at 37 °C and 5% CO2. Equal volume of DMSO was 
used as a negative control. For concentration optimization experiment, 
increasing concentrations (20-200 μM) of P2 were used to culture the cells for 
4 hrs. Subsequently, the medium was removed and cells were washed with 
PBS and detached with trypsin. The cell pellet was resuspended in PBS, 
washed, followed by sonication in 150 µl of PBS to lyse cells. The resultant 
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cell lysate was cleared by centrifuging at 13,000 rpm for 30 min. Protein 
concentrations of the cell lysates were determined using the Bradford assay. 
Equal amounts (100 μg) of different treatment samples were used for 
subsequent fluorescent labeling. For each reaction, Cy3-azide (20 μM), 
Tris(2-carboxyethyl) phosphine (TCEP) (1mM, 100×fresh stock in water), 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (TBTA ligand) (100 μM, 
100×stock in DMSO), and CuSO4 (1mM,100×stock in water) were added to 
the lysate. The samples were incubated at room temperature for 2 hrs. Next, 
clicked proteins were precipitated by acetone and air dried. 100 μL 1× SDS 
loading buffer was added to dissolve the sample and 50 μL of sample was 
separated by SDS gel electrophoresis on 10% polyacrylamide gel. After 
SDS-PAGE, gels were visualized using a Typhoon 9410 laser scanner (GE, 
health care) and images were analyzed by TotalLab software. 
 
4.2.9 Cells Labeling using andro probe 
In the subsequent ICABPP study, two biological duplicate of P2 treated and 
two DMSO treated samples were pulled down and digested in parallel. The two 
DMSO control samples were labeled with iTRAQ reagent and quantified by 
iTRAQ ratios. Briefly, HCT116 cells were grown to 80-90% confluence in 
T175 flasks. Spent medium was then aspirated and the cells washed twice with 
PBS. P2 (100 μM) in 20 ml medium with a final DMSO concentration of 1% 
was added to the cells in the flasks and incubated for 4 hrs in the CO2 
incubator.. Culture medium containing 1% DMSO was used as negative 
control. Subsequently, P2- and DMSO- containing media were removed, and 
then the cells were washed with PBS and detached with trypsin. The cell pellet 
was resuspended in PBS, washed and lysed by sonication in PBS. The cell 
lysates were clarified by centrifugation at 13,000 rpm for 30 min followed by 
Bradford protein assay. Equal amount (5 mg) of cell lysates (2 Andro probe 
treated and 2 DMSO treated samples) were used for subsequent click 
chemistry to conjugate proteins with the biotin tags separately. For each 
reaction, Biotin-azide (20 μM), Tris(2-carboxyethyl) phosphine(TCEP) (1mM, 
100× fresh stock in water), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine 
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(TBTA ligand) (100 μM, 100×stock in DMSO), and CuSO4 (1mM,100×stock 
in water) were added to the cell lysates and incubated at room temperature for 
4 hrs. Next, clicked proteins subjected to precipitation with acetone and air 
dried. Subsequently, the pellet was dissolved in 1 mL PBS and incubated with 
50 μL of Streptavidin beads (Sigma-Aldrich) under gentle mixing for 2 hrs at 
room temperature. 
 
4.2.10 On-beads Digestion 
The beads were washed a total of 9 times; thrice with 1% SDS, followed 
by 3 times with 6M urea and thrice with PBS. The extensively washed beads 
were resuspended in 25mM ammonium bicarbonate (NH4HCO3) and 2 µL 
tris-(2-carboxyethyl) phosphine (TCEP, 100 mM stock solution) added. The 
beads were placed in a 65°C heat block for 60 min. Next, 1µL methyl 
methane-thiosulfonate (MMTS, 200mM stock solution) was added and the 
samples left in the dark and allowed to react for 15 min at room temperature. 
Following reduction and alkylation, trypsin (12.5 ng/ µL, Promega) was added 
and incubated at 37°C overnight. The digested peptides were separated from 
the beads using a filter-spin column (GE, healthcare). These digested peptides 
could be stored at -20 °C for several months pending iTRAQ labeling and 
mass spectrometry analysis. 
 
4.2.11 iTRAQ Labeling of the Digested Pull-Down Samples 
iTRAQ labeling was performed out using iTRAQ Reagent kit (AB SCIEX, 
Foster City, CA, USA) based on the vender’s instruction manual with minor 
modifications. The two biological replicates of the negative control pull-down 
samples were labeled with iTRAQ reagent 113 and 114, respectively. Similarly, 
two biological replicate of digested Andro pull-down samples were labeled 
with reagent 116 and 117, respectively. Briefly, the on-beads digested peptides 
were dried and reconstituted with equal volume of dissolving buffer (0.5M 
TEAB). The peptides were then labeled with the respective iTRAQ reagents 
and incubated at room temperature for 2 hrs before all the samples were 




4.2.12 Strong Cation Exchange (SCX) Chromatography, C18 Desalting of 
Labeled Samples 
To remove interfering substances like SDS, isopropanol, dissolution 
buffer (TEAB), reducing agent (TCEP), alkylating agent (MMTS), calcium 
chloride and excess iTRAQ reagents etc., the pooled iTRAQ-labeled peptides 
sample was subjected to strong cation exchange chromatography (SCX) using 
the iTRAQ Method Development Kit (AB SCIEX, Foster City, CA, USA). 
The bound peptides were eluted with 5 % ammonium hydroxide (NH4OH) in 
30 % methanol. The eluate was desalted using a Sep-Pak C18 cartridge (Waters, 
Milford, MA), dried and then reconstituted with 100 μL of diluent (98% water, 
2% acetonitrile, 0.05% formic acid). 
 
4.2.13 Proteins Identification and Quantification  
Nano LC−ESI-MS: The detailed methods for LC-MS/MS was described 
previously (Tang et al. 2012). Briefly, separation of the iTRAQ labeled 
peptides was carried out on an Eksigent nanoLC Ultra and ChiPLC-nanoflex 
(Eksigent, Dublin, CA) in Trap Elute configuration. A volume of 5 μL of the 
sample was loaded to the LC system. Peptides were separated by a gradient 
formed by 2% ACN, 0.1% FA (mobile phase A) and 98% ACN, 0.1% FA 
(mobile phase B): 5−12% of mobile phase B (20 min), 12−30% of mobile 
phase B (90 min), 30−90% of mobile phase B (2 min), 90% of mobile phase B 
(5 min), 90−2% of mobile phase B in 3 min, and 50−5% of mobile phase B in 
13 min, at a flow rate of 300 nL/min. The MS analysis was performed on a 
TripleTOF 5600 system (AB SCIEX, Foster City, CA) in information 
dependent mode.  
ProteinPilot Analysis: The detailed method of ProteinPilot analysis was 
described previously.2 Briefly, the protein identification and iTRAQ 
quantification were performed with ProteinPilot™ 4.5 (AB SCIEX, Foster 
City, CA) which uses the Paragon™ algorithm to perform database searches. 
The database used includes the International Protein Index (IPI) v3.87 human 
protein sequences (total 91 468 entries). The search parameters used were as 
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follows: Cysteine alkylation of MMTS; Trypsin Digestion; TripleTOF 5600; 
Biological modifications. Redundancy was eliminated by the grouping of 
identified proteins using the ProGroup algorithm in the software. A decoy 
database search strategy was used to determine the false discovery rate (FDR) 
for peptide identification. A corresponding randomized database was 
generated using the Proteomics System Performance Evaluation Pipeline 
(PSPEP) feature in the ProteinPilot™ Software 4.5. In this study, a strict total 
score cut-off >1.3 was adopted as the qualification criterion, which 
corresponded to a peptide confidence level of 95%. The identification and 
quantification results were then exported into Microsoft Excel for manual data 
analysis. 
4.2.14 Data Analysis 
To determine the cut-off threshold for the fold change of proteins 
identified from the iTRAQ study to be considered as significantly regulated, 
two equal amounts of six-protein mixtures (Applied Biosystems) were 
trypsin-digested and labeled with the iTRAQ reagents.3 The standard deviation 
(S.D) of all the ratios of the labeled peptides was computed to be 0.15. Thus 
by using a 1 + 2 S.D formula the fold-change cut-off thresholds were set as 1.3 
for up-regulated proteins and reciprocally 0.77 for down-regulated proteins. 
This strategy was adopted for our quantitative study. This cut-off was used to 
eliminate protein targets where the two biological replicate samples showed 
significant change (ratio >1.3 or <0.77). Basing on this strategy, 208 proteins 
were considered to be the statistically reliable hits (Figure 2.6), and the 
distribution of the enrichment ratios of these proteins were further presented as 
the colored heat map as illustrated in Figure 2.7. The 4 set ratios of Andro 
pull-down vs. DMSO pull-down were presented as colored heatmap, using the 
MultiExperiment Viewer (MeV) (Saeed et al. 2006; Saeed et al. 2003). 
Proteins with enrichment ratio closed to 1 are denoted in blue and likely to 
exhibit non-specific binding. In contrast, proteins labeled in red showed 
enrichment ratio above 2 or close to 3, suggesting that they are likely the 
specific binding targets.  
To reduce the likelihood of selecting the false positive drug targets, we 
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chose a stringent ratio equivalent to 2 as the cut-off to identify specific protein 
targets for subsequent experiments. Meanwhile, proteins identified based on a 
single peptide are considered unreliable and were removed. Using these criteria, 
75 proteins were identified and selected (Figure 2.6). The full list of the 75 
potential targets is shown in Supplemental Table of chapter 2. 
 
4.2.15 Pathway Analysis of Andro Targets 
The specific Andro targets identified using the ICABPP approach were 
analyzed using the Ingenuity Pathway Analysis software (Ingenuity® Systems, 
Redwood city, CA, USA). A spreadsheet containing the list of Andro targets 
was uploaded into IPA. The software mapped each of the proteins to the 
repository of information in the Ingenuity Pathways Knowledge base. 
Molecular networks and canonical pathways regulated by these drugs targets 
were obtained using IPA core analysis.  
 
4.2.16 Validation of Drug Target using Western Blot 
Andro probe affinity pull-down sample was separated by 1D-SDS PAGE 
together with DMSO pull-down sample. After SDS-PAGE, the proteins were 
transferred onto PVDF membranes (Bio-Rad). The blots were blocked with 5% 
(w/v) BSA in PBS with 0.1% Tween 20 (PBS-T) for 4hrs at room temperature. 
The membranes were incubated with rabbit anti- NF-κB p50 (1:1500), from 
Santa Cruz Biotechnology, Inc. as well as mouse anti- -actin (1:4000) from 
BD Transduction Laboratories. HRP-conjugated from Pierce Biotechnology, 
or HRP-conjugated anti-mouse IgG (1:5000) from GE Healthcare were used 
as secondary antibodies and incubated for 2 hrs at room temperature. The 
membrane was washed 3 times in PBS-T between each antibody incubation 








4.2.17 Expression of Wild Type and Mutated NF-κB p50 
DNA insert of P50 Rel homology domain (aa 39-364), a gift from Prof. G. 
Ghosh of UCSD, was subcloned into pET-M expression vector. P50-C62A 
mutant was generated by PCR-based site-directed mutagenesis method. The 
plasmids were transformed into E. coli BL21 (DE3) cells for protein 
expression. A single colony of E.coli BL21 (DE3) cells containing the desired 
plasmid was cultured overnight in 10 ml LB medium containing 100 µg/ml 
ampicillin. Two milliliters of overnight cultures were inoculated into 1L LB 
broth culture medium containing 100 µg/ml ampicillin. The culture was grown 
at 37°C until OD600 of 0.6 was reached. Protein expression was induced with 
0.35 mM of IPTG at 37 °C for overnight. The cell suspension was harvested 
and resuspended in Ni binding buffer containing 20 mM Tris-Cl pH 8.0, 0.5 M 
NaCl, 5 mM Immidazole. The cell suspension was lysed by sonication on ice 
and subsequently centrifuged at 18,000x g for 30 min. The supernatant of the 
cell lysate was loaded on the Ni column and the column was washed 10 times 
with a total volume of 500 ml Ni washing buffer containing 20 mM Tris-Cl 
pH8.0, 0.5 M NaCl, 30 mM immidazole to remove unbound proteins. 
Recombinant p50 with Histidine tag was eluted with 20 mM Tris-Cl pH8.0, 
0.5 M NaCl, 500 mM Immidazole. The eluted p50 was dialyzed overnight 
against 1xPBS pH 7.3 to remove imidazole. This protein was subsequently 
further purified using gel filtration column Superdex 200 (Amersham). 
 
4.2.18 In vitro Labeling of Human Recombinant NF-κB p50  
Recombinant NF-κB p50 was reconstituted with PBS as 1 mg/ml. 1 μL 
protein solution was diluted with 42 μL PBS and incubated with 1 μL P2 at a 
final concentration of 0, 10, 20, 40, 80, 160 μM for 4 hrs, followed by Click 
reaction, SDS-PAGE and fluorescence scanning. For heat denatured sample, 1 
μL protein solution was diluted with 40 μL PBS and 2 μL of 25% SDS and the 
sample was heated at 96 °C for 10 min. Then the heated sample was cooled to 
room temperature and reacted with 80 μM P2 at. Competition assay was 
carried out with the pre-treatment of 10× excess free Andro for 4 hrs, and then 
labeled with P2. 1mM DTT or 5mM BME co-treatment together with Andro 
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were also included in our experiment. Mutated C62A p50 was labeled with 80 
μM to test this critical amino acid in Andro reaction. 
 
4.2.19 Andro Binding Site Mapping of NF-κB p50 
To map out the exact binding site of Andro in NF-κB p50, the 
recombinant p50 was treated with Andro or DMSO. After trypsin digestion, 
the resulting peptides were analyzed by MS/MS. Briefly, 1 µL of 10 mM 
Andro or 1 μL DMSO was incubated with 50 μg NF-κB in 100 μL PBS for 4 
hrs at room temperature. The labeled samples were buffer exchanged against 
50 mM NH4HCO3 to remove unbound drug using a filter spin column (10 kDa 
cut-off). The final solution volume was adjusted to 50 µL using 50 mM 
NH4HCO3. This was followed by the addition of 1 μg trypsin to the NF-κB 
samples and incubated for 16 hrs at 37°C. The digested samples were analyzed 
by high resolution LC-MS/MS. The MS/MS spectra of the native NF-κB 
peptide containing Cys62 are shown in Figure 2.13 (top). The MS/MS spectra 
of the Andro labeled NF-κB peptide containing Cys62 are shown in Figure 
2.13 (bottom). CA* represents the Andro modified Cys. Peptide ions containing 
modified Cys are indicated A* in red.  
 
4.2.20 Molecular Docking 
Autodock is an automated procedure for predicting optical conformations 
and orientations for the ligand, protein or DNA with the target proteins at the 
binding site (Morris et al. 1998)(Morris et al. 2009). NF-κB-Andro docking 
simulations were performed using Autodock version 4.2 
(http://autodock.scripps.edu/) with the Lamarckian Genetic algorithm (LGA) 
method. Polar hydrogen atoms were added to the target protein p50 and its 
nonpolar hydrogens were merged. The molecule Andro was treated as flexible 
ligand and only torsions of freedom were explored, keeping both bond angles 
and lengths constant. The grid box was centered on p50 (PDB: 2V2T) with a 
dimension of 100×100×100 points. Each docking simulation was repeated 20 
times using different random generator seeds. The interactions of complex 
p50-Andro conformations were analyzed using Pymol. 
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4.2.21 In vitro Labeling of Human Recombinant -actin 
-actin from human platelet ((>99% pure), Cytoskeleton, Inc.) were 
reconstituted as 1mg/ml in G-buffer (2 mM Tris-HCl, 0.2 mM ATP, 0.2 mM 
CaCl2, 0.2 mM DTT, 0.005% NaN3, pH 8.0) or F-buffer (2 mM Tris-HCl, 2 
mM MgCl2, 100 mM KCl, 0.2 mM DTT, 0.2 mM CaCl2, 0.5 mM ATP, pH 7.5), 
incubated for 18 hrs at room temperature. 1 μL protein in G-buffer or F-buffer 
was diluted with respective buffers and incubated with 1 μL P2 at a final 
concentration of 0, 10, 20, 50 or100 μM for 4hrs, followed by Click reaction, 
SDS-PAGE and fluorescence scanning. For heat-denatured sample, 1 μL 
protein in F-buffer was diluted with 40 μL F-buffer and 2 μL of 25% SDS and 
the samples were heated at 96 °C for 10 min. The heat-denatured control was 
subsequently cooled to room temperature and reacted with P2 at 100μM.  
 
4.2.22 Andro Binding Site Mapping of -actin 
To indentify the exact binding site of Andro in -actin, the polymerized 
actin was treated with Andro or DMSO. After chymotrypsin digestion, the 
resulting peptides were analyzed by MS/MS. Briefly, 1 µL of 10 mM Andro or 
1 μL DMSO was incubated with 50 μg polymerized actin in F-buffer (2 mM 
Tris-HCl, 2 mM MgCl2, 100 mM KCl, 0.2 mM DTT, 0.2 mM CaCl2, 0.5 mM 
ATP, pH 7.5) for 4 hrs in room temperature. The labeled samples were buffer 
exchanged against 50 mM NH4HCO3 to remove unbound drug using a filter 
spin column (10 kDa cut-off). The final solution volume was adjusted to 50 µL 
using 50 mM NH4HCO3. 1 μg chymotrypsin was added to the -actin samples 
and incubated for 16 hrs at 37°C. The digested samples were analyzed by high 
resolution LC-MS/MS. The MS/MS spectra of the native -actin peptide 
containing Cys272 are shown in Figure 2.17 (top). The MS/MS spectra of the 
Andro labeled -actin peptide containing Cys272 are shown in Figure 2.17 
(bottom). CA* represents the Andro modified Cys. Peptide ions containing 







4.2.23 Cell Cycle Determination by Flow Cytometry 
Andro’s effect on cell cycle was evaluated by flow cytometry. Briefly, 
after the designated treatments, cells were detached using trpsin-EDTA. The 
cells were collected and washed 2× with PBS, then fixed and permeabilized in 
70% pre-chilled ethanol for at least 2 hrs. Fixed cells were stained with PI 
staining solution (0.1% Triton X-100, 200 mg/ml RNaseA and 20 mg/ml PI in 
PBS) for 15 min at 37°C. Subsequently, the PI stained sample were detected 
by flow cytometry analysis. 
 
4.2.24 Transwell Migration Assay 
Migration assay was carried out using 8.0 μm cell culture insert for 24 
well (BD Biosciences, San Jose, CA) according to manufacturer’s protocol. 
Briefly, the inserts were coated with 10 μg/ml fibronectin (Sigma, St. Louis, 
MO) in PBS overnight at 4 oC. The coated inserts were washed once with PBS 
before using. HCT116 were seeded at a density of 50,000 cells into the top 
chamber of each insert with 5 μM of Andro or RA in media without FBS. 
Media containing 5 μM of respective drugs were supplemented with FBS and 
added to the bottom chamber. 1% DMSO was used as negative control. After 
incubation for 30 hrs, cells from the top layer of the inserts were removed by 
scrubbing. Subsequently, the inserts were fixed in 3% paraformaldehyde 
(Sigma, St. Louis, MO) in PBS for 20 min before staining with crystal violet 
for 30 min. Excess stain was washed off and the inserts were allowed to dry. 
Solubilization was done using 1% SDS for 2 hrs and the absorbance were 
measured at 550nm. 
 
4.2.25 Matrigel Invasion Assay 
Matrigel invasion assay was carried out using matrigel coated inserts for 
24 -well plate (BD Biosciences, San Jose, CA) according to manufacturer’s 
protocol. 150,000 cells were seeded into the top chamber of each insert with 
Andro or RA in media without FBS. Media containing 5μM of respective 
drugs were supplemented with FBS and added to the bottom chamber. After 
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30 hrs incubation, cells from the top layer of the inserts were removed by 
scrubbing. Subsequently, the inserts were fixed in 3% paraformaldehyde 
(Sigma, St. Louis, MO) in PBS for 20 min before staining with crystal violet 
for 30 min. Excess stain was washed off and the inserts were allowed to dry. 
Cells from 5 randomly selected fields were counted using photographs taken 
under a light microscope at 200x magnification. 
 
4.3 Materials and methods Chapter 3 
 
4.3.1 Reagents and antibodies  
 
The chemicals used in our experiments were: bafilomycin A1 (Sigma, 
B1793), pp242 (Sigma, P0037), rapamycin (Sigma, R8781), Torin 1 (Tocris 
Bioscience, #4247), dimethyl sulfoxide (DMSO, Sigma, D2650), AHA 
(L-azidohomoalanine) reagent (Invitrogen, #C10289), tris 
[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (TBTA, Sigma, #678937), Tris 
(2-carboxyethyl) phosphine (TCEP, Sigma, C4706), CuSO4(sigma, #451657), 
TAMRA alkyne (Invitrogen, #A10267), Dulbecco’s Modified Eagle Medium 
(DMEM containing 4500 mg/L D-glucose, without L-glutamine, sodium 
pyruvate, L-methionine, and L-cystine) (Invitrogen, #21013), dialyzed fetal 
bovine serum (Invitrogen, # 26400044), methanol (Sigma, #34860), 4% 
formaldehyde in PBS, 0.5% TritonTM X-100 in PBS, 3% Bovine serum 
albumin (BSA) in PBS (3% BSA in PBS, pH 7.4), 1% SDS in 50 mM 
Tris-HCl (pH 8.0), and amino acid-free medium.  
The antibodies used in our experiments included: microtubule-associated 
protein 1 light chain 3 (LC3, Sigma, L7543), p62 (Sigma, P0067), Atg7 
(ProScience, #3617), Atg5 (Nanotools, #0262), β-actin (Sigma, A5441), 
phospho-S6 (S235/236) (Cell Signaling Technology, #2211), S6 (Cell 
Signaling Technology, #2217), phospho-4E-BP1 (Thr37/46) (Cell Signaling 





4.3.2 Cell culture 
Atg5 wild type (Atg5 WT) and Atg5 knockout (Atg5 KO) MEFs were 
kindly provided by Dr. N Mizushima (Kuma, Hatano et al. 2004; Hosokawa, 
Hara et al. 2006). Atg7 WT and Atg7 KO MEFs were kindly provided Dr. M 
Komatsu (Komatsu, Waguri et al. 2005). All cell lines were maintained in 
DMEM (Sigma, #D1152) containing 10% fetal bovine serum (HyClone, 
SV30160.03) in a 5% CO2 atmosphere at 37Ԩ. 
 
4.3.3 Metabolic labeling of newly synthesized proteins with AHA  
As shown in Figure 3.1A, AHA is an effective surrogate for methionine, 
an essential amino acid, that does not require any further manipulations to be 
incorporated as a substrate by the methionyl-tRNA synthetase into the proteins 
during de novo protein synthesis (Kiick, Saxon et al. 2002; Link and Tirrell 
2003).  
The cells with 70~80% confluency in a 6-well plate were washed with 
warm PBS and cultured in L-methionine-free DMEM for 30 min to deplete the 
intracellular methionine reserves. Following methionine depletion, the cells 
were labeled with AHA in 10% FBS DMEM (methionine-free) for 18 h. In 
this assay, dialyzed FBS was used to eliminate L-methionine from other 
source. After labeling, the cells were washed with PBS and cultured in regular 
DMEM containing 10x L-methionine (2 mM) for 2 h to chase out 
short-termed proteins. The cells then underwent various treatments as 
designated.  
 
4.3.4 Cell fixation and permeabilization  
After incubation, the medium containing AHA was removed and the cells 
were washed once with PBS. Following the removal of PBS, cells were treated 
as designated experiments. The cells were then harvested and fixed in 4% 
formaldehyde in PBS for 15 min at room temperature. After fixation, the cells 
were washed twice with 3% BSA in PBS and permeabilized with 0.5% 
TritonTM X-100 in PBS for 20 min at room temperature. Finally, the cells were 
resuspended in PBS and stored at 4Ԩ for the detection of corresponding 
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alkyne-tagged detection molecule.  
 
4.3.5 Click AHA Detection 
The amount of AHA incorporated into the protein can be detected using 
the “click” reaction between an azide and an alkyne (Dieterich, Link et al. 
2006), and a broad range of functionally and biochemically diverse proteins 
that incorporated with AHA can be specifically tagged with a corresponding 
alkyne-containing dye or hapten, and subject to subsequent analysis by flow 
cytometry or standard biochemistry techniques such as gel electrophoresis 
(Figure 3.1B).  
Before click reaction, the cells were washed by PBS and 3% BSA. For 
each reaction, TAMRA alkyne (10μM), Tris (2-carboxyethyl) phosphine 
(TCEP) (1 mM, 100x fresh stock in water), 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (TBTA ligand) (100 μM, 
100×stock in DMSO), and CuSO4 (1 mM,100x stock in water) were added 
into the suspended cells. The samples were incubated at room temperature for 
2 h, and then the reaction cocktail was removed and the cells were washed 
once with 3% BSA in PBS.  
 
4.3.6 In Gel fluorescence detection 
After AHA labeling, the cells were lysed in 0.2% SDS in PBS. Equal 
amounts (100 μg) of proteins were tagged with the fluorescent dye and clicked 
proteins were precipitated by acetone and air-dried. 1× SDS loading buffer 
(100 μL) was added to dissolve the sample and the sample (50 μL) was 
separated by 10% SDS gel electrophoresis. Finally, gels were visualized using 
a Typhoon 9410 laser scanner (GE, health care) and images were analyzed by 
TotalLab software. 
 
4.3.7 Analysis of AHA signal intensity using flow cytometry. 
After fluorescence tagging, nascent protein synthesis was assessed by 
flow cytometry and AHA signal intensity was determined in the FITC channel. 
We quantified the cell’s fluorescence intensity and calculated the ratio of the 
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treated cell’s fluorescence intensity to the control cell’s fluorescence intensity. 
This represented the rate of degradation of long-lived proteins at given time 
points. The average and standard deviation were calculated as follows:  
Relative fluorescence intensity (%) = (treated group – negative control) / 
(control group – negative control) × 100 
Based on the AHA labeling and click reaction as described above, we here 
developed a protocol for quantification of the long-lived protein degradation in 
autophagy, as shown in Figure 3.2.  
 
4.3.8 Autophagy induction and inhibition 
The cells were labeled with AHA as described above and cultured in 
common medium with 10× L-methionine (2 mM) for 2 h to chase out 
short-termed protein in the presence or absence of autophagy inhibitors 
(wortmannin and bafilomycin A1). The medium was removed by aspiration 
and the cells were then incubated in amino acid-free medium (plus 0.1% of 
bovine serum albumin and 2 mM L-methionine) or treated with mTOR 
inhibitors (rapamycin, pp242 or Torin 1) to induce autophagy in the presence 
or absence of autophagy inhibitors at indicated time points.  
 
4.3.9 Western blotting 
At the end of the designated treatments, cells were lysed in Laemmli SDS 
buffer (62.5 mM Tris at pH 6.8, 25% glycerol, 2% SDS, phosphatase inhibitor 
and proteinase inhibitor cocktail). An equal amount of protein was resolved by 
SDS-PAGE and transferred onto PVDF membrane. After blocking with 5% 
non-fat milk, the membrane was probed with designated primary and 
secondary antibodies, developed with the enhanced chemiluminescence 
method and visualized with the Kodak Image Station 4000R (Kodak).  
 
4.3.10 Statistical Analysis 
All western blot and image data presented are representatives from at least 
three independent experiments. The numeric data are presented as means ± SD 






  Chapter 5
 
Concluding Remarks and future direction 
 
In summary, we have described several proteomics approaches, including 
identification-based, quantitative and chemical proteomics methods. We have 
successfully demonstrated the potential of these methods in disease 
mechanism, drug target and autophagy proteolysis studies. 
In the first part of this thesis, we described a novel approach combining 
isobaric tag for relative and absolute quantification (iTRAQ) with Clickable 
ABPP, named ICABPP, to specifically and comprehensively identify drug 
targets in live cells. This approach was applied to identify the protein targets of 
andrographolide (Andro), a natural product with known anti-inflammatory and 
anti-cancer effects, in live cancer cells. A spectrum of specific targets of Andro 
was identified, revealing the mechanism of action of the drug and its potential 
novel application as a tumor metastasis inhibitor, which was validated through 
cell migration and invasion assays. Moreover, the target binding mechanism of 
Andro was unveiled with a combination of drug analogue synthesis, protein 
engineering and mass spectrometry-based approaches and the drug-binding 
sites of two protein targets, NF-B and actin, were determined. 
Our ICABPP approach can be easily optimized and applied to various 
kinds of affinity chromatography or ABPP-based target identification 
processes. Currently, besides andrographolide, we have already designed and 
synthesized several other drug probes for unbiased specific targets 
identification, including artemisinin, curcumin, celastrol, triptolide and aspirin 
(figure 5.1). Using our recently developed ICABPP method, we have also 
identified the specific targets of these drugs. 
As shown in figure 5.2, our celastrol probes can specifically label a set of 
proteins in comparison with DMSO control. From our LC-MS/MS data, 
several previously reported celastrol targets have been successfully identified 
(Table 5.1). Target validation experiments are in progress and will be reported 
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in due course in future. Our results showed that ICAPP methods can be easily 
used for target identification for different kinds of drugs. We anticipate it to be 
































Figure 5.1  Drugs that have been successfully developed into activity based 




Figure 5.2 The in situ fluorescent labeling of HCT116 cells using celastrol 
probe (2 µM) together with a DMSO-treated negative control. Probe-labeled 
proteomes were visualized by click conjugation to the Cy3 azide tag, SDS-gel 





Score Accession No. Name 
26.9 sp|P15121|ALDR_HUMAN Aldose reductase 
3.7 sp|O14965|AURKA_HUMAN Aurora kinase A 
9.3 sp|Q96GD4|AURKB_HUMAN Aurora kinase B 
2.7 sp|Q9HB09|B2L12_HUMAN Bcl-2-like protein 12 
20.5 sp|P10644|KAP0_HUMAN cAMP-dependent protein kinase type I-alpha regulatory subunit 
13.4 sp|P13861|KAP2_HUMAN cAMP-dependent protein kinase type II-alpha regulatory subunit 
8.8 sp|P26358|DNMT1_HUMAN DNA (cytosine-5)-methyltransferase 1 
3.3 sp|P28340|DPOD1_HUMAN DNA polymerase delta catalytic subunit 
12.7 sp|Q02750|MP2K1_HUMAN Dual specificity mitogen-activated protein kinase kinase 1 
4.7 sp|P33981|TTK_HUMAN Dual specificity protein kinase TTK 
29.1 sp|Q9HC38|GLOD4_HUMAN Glyoxalase domain-containing protein 4 
 
Table 5.1  Potential celastrol targets identified using ICABPP approach, 




In the second part of my thesis, we have successfully developed a novel 
method by using AHA labeling as a simple, sensitive, specific and quantitative 
tool to measure autophagic protein degradation. This assay is mainly 
applicable to cell culture systems in vitro and it could be easily adapted for 
high-throughput screening of autophagy modulators. 
In future, we will focus on individual protein degradation rate and reveal 
inherent protein intracellular stability. Following AHA labeling, subcellular 
fractionation and affinity enrichment of protein complexes can be prepared 
and mass spectrometry will be performed to assess the temporal and spatial 
dynamics of certain subcellular compartments, organelles and protein-protein 
interaction networks.  
Other than the proteolysis level in autophagy, we are also interested in the 
newly synthesized proteins during autophagy induction. Theoretically, 
autophagy is a process under the extreme nutrition deprivation condition, 
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during which the protein synthesis pathway should been shut down or kept at a 
very low level. To test this, we have incubated the starved cell with AHA for 
4hrs to label the newly synthesized protein during autophagy induction. Our 
preliminary results showed there are definitely some proteins newly 
synthesized even under the starvation condition with amino acid free media 





Figure 5.3  The in situ fluorescent labeling of newly synthesized proteins of 
Hela cells under normal and starvation conditions. Cells were cultured in full 
media or amino acid free media (EBSS) for 0.5, 2 and 4hrs. Cycloheximide 
(CHX) was added to inhibit the protein synthesis. AHA (50 µM) labeled 
proteomes were visualized by click conjugation to the Cy3 alkyne tag, 
SDS-gel separation, and fluorescent scanning. The coomassie staining showed 
the equal protein loading. 
 
 
We have successfully identified some of the newly synthesized proteins 
during autophagy and carried out the pathway analysis. As shown in figure 5.4, 





Figure 5.4  IPA pathways analysis of the newly synthesized proteins during 
autophagy inductions. The results suggested these newly synthesized proteins 
may sustain cell survival, decrease cell death and decrease protein synthesis. 




sustaining cell survival and decreasing cell death, which is consistent with the 
fact that autophagy is a cell survival process. More detailed mechanistic study 
and validation are needed in future to clearly delineate the roles of these newly 
synthesized proteins during autophagy. 
In summary, the quantitative chemical proteomics approaches developed 
and used in this thesis should be extremely useful in drug target identification 
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Supplemental Table of Chapter 3 
Supplemental Table  Specific Andro targets identified using ICABPP approach. All the proteins listed below were identified and 
quantified by at least two peptides. These proteins were all enriched two times by the Andro probe compared to DMSO-treated control. 












1  35.65  37.6  IPI00414676  HSP90AB1 Heat shock protein HSP 90‐beta  HSP90AB1  19  2.13  2.13  2.40  2.39  1.18  2.26  0.0002 
2  32.61  60.7  IPI00021439  ACTB Actin, cytoplasmic 1  ACTB  27  2.71  2.75  2.88  2.92  1.49  2.81  1E‐05 
3  30.15  21.6  IPI00019502  MYH9 Isoform 1 of Myosin‐9  MYH9  15  2.33  2.55  2.40  2.61  1.30  2.47  6E‐05 
4  29.26  24.5  IPI00939304  IPO5 Isoform 3 of Importin‐5  IPO5  16  3.46  3.39  4.03  3.95  1.89  3.70  9E‐05 
5  28.17  44.4  IPI00479186  PKM2 Isoform M2 of Pyruvate kinase isozymes M1/M2  PKM2  14  2.05  2.02  2.21  2.19  1.08  2.11  6E‐05 
6  26.62  46.4  IPI01022164  TUBB Uncharacterized protein  TUBB  17  2.15  1.67  2.78  2.19  1.11  2.16  0.0051 
7  24.52  38.2  IPI00784154  HSPD1 60 kDa heat shock protein, mitochondrial  HSPD1  13  1.96  2.06  2.03  2.12  1.03  2.04  3E‐05 
8  24.4  30.1  IPI00186290  EEF2 Elongation factor 2  EEF2  14  1.94  1.87  2.29  2.18  1.04  2.06  0.0006 
9  19.94  53.9  IPI00465248  ENO1 Isoform alpha‐enolase of Alpha‐enolase  ENO1  11  2.12  2.09  2.27  2.23  1.12  2.17  4E‐05 
10  19.65  39.3  IPI00930688  TUBA1B Tubulin alpha‐1B chain  TUBA1B  10  2.25  2.28  2.52  2.56  1.26  2.40  0.0001 
11  16.02  46.8  IPI00947127  LDHA L‐lactate dehydrogenase A chain isoform 3  LDHA  8  2.12  2.18  2.41  2.48  1.20  2.29  0.0002 
12  15.33  16.8  IPI00333541  FLNA Isoform 1 of Filamin‐A  FLNA  7  2.09  2.15  1.85  1.92  1.00  2.00  0.0003 
13  14.14  32.9  IPI00784090  CCT8 T‐complex protein 1 subunit theta  CCT8  7  2.18  2.37  2.23  2.40  1.20  2.30  5E‐05 
14  13.24  41.6  IPI00219217  LDHB L‐lactate dehydrogenase B chain  LDHB  7  1.96  1.98  2.16  2.19  1.05  2.07  0.0001 
15  12.97  29.7  IPI00472724  EEF1A1P5;EEF1A1 Putative elongation factor 1‐alpha‐like 3  EEF1A1  7  2.33  2.40  2.37  2.44  1.25  2.38  4E‐06 
16  16.74  29  IPI00304925  HSPA1B;HSPA1A Heat shock 70 kDa protein 1A/1B  HSPA1A  9  2.25  2.08  2.05  1.90  1.05  2.07  0.0002 
17  12.35  19.9  IPI00008164  PREP Prolyl endopeptidase  PREP  7  2.97  3.17  3.35  3.56  1.70  3.26  8E‐05 
18  12.29  30  IPI00003918  RPL4 60S ribosomal protein L4  RPL4  8  2.13  2.13  2.30  2.29  1.14  2.21  4E‐05 
19  11.72  11  IPI00910701  AARS cDNA FLJ61339, highly similar to Alanyl‐tRNA synthetase  AARS  6  2.06  2.03  2.28  2.20  1.10  2.14  0.0001 
20  11.15  34.2  IPI00550021  SNORD43;RPL3 60S ribosomal protein L3  RPL3  6  1.88  2.06  2.00  2.19  1.02  2.03  0.0002 
21  10.71  16.9  IPI00918003  SSFA2 Uncharacterized protein  SSFA2  5  2.45  2.04  2.20  1.84  1.08  2.12  0.0011 
22  10.39  42.7  IPI00982101  YWHAZ Uncharacterized protein  YWHAZ  8  2.26  2.48  2.12  2.32  1.20  2.29  0.0001 
23  10.21  26.2  IPI00549248  NPM1 Isoform 1 of Nucleophosmin  NPM1  6  2.43  2.36  2.57  2.50  1.30  2.46  2E‐05 
24  9.74  15.5  IPI00930205  SYNCRIP heterogeneous nuclear ribonucleoprotein Q isoform 5  SYNCRIP  6  2.15  1.86  2.38  2.04  1.07  2.10  0.0007 
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25  9.71  68.6  IPI00216691  PFN1 Profilin‐1  PFN1  6  2.09  2.00  2.13  2.04  1.05  2.06  1E‐05 
26  9.12  19.9  IPI00008530  RPLP0 60S acidic ribosomal protein P0  RPLP0  5  1.88  1.85  2.34  2.29  1.05  2.08  0.0013 
27  8.92  10.4  IPI01015455  CPS1 166 kDa protein  CPS1  4  2.32  2.53  2.00  2.31  1.19  2.28  0.0005 
28  8.51  14.6  IPI00556541  CARS cDNA FLJ38994 fis, clone NT2RI2009259, highly similar to Cysteinyl‐tRNA synthetase  CARS  4  2.54  2.76  2.80  3.04  1.47  2.78  1E‐04 
29  8.49  25.1  IPI00025491  EIF4A1 Eukaryotic initiation factor 4A‐I  EIF4A1  4  2.10  2.16  2.02  2.07  1.06  2.09  2E‐05 
30  8.27  13.1  IPI00645078  UBA1 Ubiquitin‐like modifier‐activating enzyme 1  UBA1  4  2.14  2.35  2.41  2.63  1.25  2.38  0.0002 
31  8.18  25.7  IPI01015770  HNRNPK cDNA FLJ53312, highly similar to Heterogeneous nuclear ribonucleoprotein K  HNRNPK  4  2.35  2.19  2.17  2.03  1.13  2.18  0.0001 
32  8.15  31.3  IPI00797270  TPI1;TPI1P1 Isoform 1 of Triosephosphate isomerase  TPI1  4  2.00  1.98  2.70  2.65  1.21  2.31  0.0023 
33  8  18.1  IPI00093057  CPOX Coproporphyrinogen‐III oxidase, mitochondrial  CPOX  5  2.09  2.60  1.97  2.46  1.18  2.26  0.0011 
34  7.9  56.1  IPI00640741  PRDX1 19 kDa protein  PRDX1  5  2.24  2.22  2.08  2.07  1.10  2.15  5E‐05 
35  7.81  28.5  IPI00007188  SLC25A5 ADP/ATP translocase 2  SLC25A5  4  1.98  2.29  1.88  2.18  1.05  2.08  0.0005 
36  7.69  37.1  IPI00215777  SLC25A3 Isoform B of Phosphate carrier protein, mitochondrial  SLC25A3  4  2.58  2.76  2.11  2.26  1.27  2.42  0.0007 
37  7.53  17.3  IPI00291510  IMPDH2 Inosine‐5'‐monophosphate dehydrogenase 2  IMPDH2  4  1.99  2.03  2.01  2.09  1.02  2.03  6E‐06 
38  7.52  11.3  IPI00927765  EIF4G1 Uncharacterized protein  EIF4G1  4  1.84  1.92  2.19  2.23  1.03  2.04  0.0007 
39  7.41  50.3  IPI00419585  PPIA Peptidyl‐prolyl cis‐trans isomerase A  PPIA  5  2.24  2.16  2.38  2.32  1.19  2.27  4E‐05 
40  7.22  38.9  IPI00867533  RPL6 60S ribosomal protein L6  RPL6  4  1.80  1.90  2.21  2.33  1.03  2.05  0.0013 
41  7.12  17.3  IPI00908896  HNRNPH1 Uncharacterized protein  HNRNPH1  4  2.16  2.16  2.90  2.82  1.31  2.48  0.0015 
42  7.06  34.5  IPI01014620  NME1;NME2;NME1‐NME2 Uncharacterized protein  NME1  4  2.02  1.80  2.32  2.07  1.03  2.04  0.0008 
43  6.9  18.1  IPI00893179  XRCC6 X‐ray repair complementing defective repair in Chinese hamster cells 6  XRCC6  3  1.88  2.66  1.74  2.44  1.10  2.14  0.005 
44  6.67  19.6  IPI00299573  RPL7A;SNORD24 60S ribosomal protein L7a  RPL7A  3  2.07  2.24  1.95  2.11  1.06  2.09  0.0001 
45  6.54  19.3  IPI00010796  P4HB Protein disulfide‐isomerase  P4HB  4  1.90  1.77  2.50  2.32  1.07  2.10  0.0029 
46  6.13  10.1  IPI00788987  NFKB1 Isoform 1 of Nuclear factor NF‐kappa‐B p105 subunit  NFKB1  4  2.88  3.40  2.34  2.72  1.49  2.81  0.0009 
47  6  26.2  IPI00219757  GSTP1 Glutathione S‐transferase P  GSTP1  3  2.06  2.28  2.11  2.35  1.14  2.20  0.0001 
48  5.82  12.2  IPI00383296  HNRNPM Isoform 2 of Heterogeneous nuclear ribonucleoprotein M  HNRNPM  3  2.23  2.36  2.49  2.64  1.28  2.42  0.0002 
49  5.54  5.9  IPI00646493  COPA Isoform 2 of Coatomer subunit alpha  COPA  3  2.67  2.27  2.92  2.51  1.37  2.58  0.0004 
50  5.47  15.6  IPI01015591  DHX15 Uncharacterized protein  DHX15  3  1.81  2.06  2.59  2.85  1.19  2.29  0.0041 
51  4.68  14.6  IPI00815732  PAICS Isoform 2 of Multifunctional protein ADE2  PAICS  3  2.22  1.74  2.59  2.08  1.10  2.14  0.0027 
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52  4.87  14.3  IPI00925572  ASNS asparagine synthetase [glutamine‐hydrolyzing] isoform b  ASNS  2  2.51  2.24  2.52  2.22  1.24  2.37  0.0001 
53  8.74  29.8  IPI00018146  YWHAQ 14‐3‐3 protein theta  YWHAQ  6  2.25  2.28  2.21  2.26  1.17  2.25  9E‐07 
54  4.64  60.3  IPI00966243  CYB5B Uncharacterized protein  CYB5B  2  3.66  3.39  3.51  3.25  1.79  3.45  2E‐05 
55  4.59  38.7  IPI00979595  RPS2 Uncharacterized protein  RPS2  3  1.91  1.91  2.46  2.47  1.12  2.17  0.0018 
56  4.21  10.4  IPI00016610  PCBP1 Poly(rC)‐binding protein 1  PCBP1  2  2.72  2.73  3.02  3.03  1.52  2.87  5E‐05 
57  4.11  20.1  IPI01025218  SNORD84;DDX39B Uncharacterized protein  DDX39B  2  2.26  2.00  2.52  2.22  1.16  2.24  0.0005 
58  4.05  25.7  IPI00909207  PRDX2 cDNA FLJ60461, highly similar to Peroxiredoxin‐2  PRDX2  2  2.44  2.22  2.58  2.33  1.26  2.39  0.0001 
59  4.03  23.6  IPI00024933  RPL12 Isoform 1 of 60S ribosomal protein L12  RPL12  2  1.91  2.06  1.99  2.15  1.02  2.03  9E‐05 
60  4.02  15.7  IPI00465233  EIF3L Uncharacterized protein  EIF3L  3  2.01  2.34  1.90  2.23  1.08  2.11  0.0006 
61  4.03  9.5  IPI00303476  ATP5B ATP synthase subunit beta, mitochondrial  ATP5B  2  1.98  2.80  1.59  2.24  1.08  2.11  0.0081 
62  4  47.7  IPI00024919  PRDX3 Thioredoxin‐dependent peroxide reductase, mitochondrial  PRDX3  2  2.73  1.94  2.66  1.89  1.18  2.27  0.0037 
63  4  17.7  IPI00221091  RPS15A 40S ribosomal protein S15a  RPS15A  2  2.12  1.86  2.20  1.93  1.02  2.02  0.0004 
64  4  8.5  IPI00642936  GSTO1 glutathione S‐transferase omega‐1 isoform 3  GSTO1  2  1.61  2.39  1.97  2.92  1.12  2.17  0.009 
65  4  13.6  IPI00555744  RPL14 Ribosomal protein L14 variant  RPL14  2  3.20  2.89  2.64  2.38  1.47  2.76  0.0005 
66  4  32.6  IPI00221093  RPS17;RPS17L 40S ribosomal protein S17  RPS17  3  1.93  1.90  2.72  2.69  1.19  2.28  0.0037 
67  4  5.9  IPI00105598  PSMD11 Proteasome 26S non‐ATPase subunit 11 variant (Fragment)  PSMD11  2  2.16  1.92  3.03  2.59  1.26  2.39  0.0033 




VDAC2  3  2.07  2.45  2.15  2.52  1.19  2.29  0.0004 
69  3.67  29.4  IPI00030179  RPL7P32;RPL7 60S ribosomal protein L7  RPL7  2  1.78  2.95  1.84  3.03  1.22  2.33  0.0101 
70  3.61  14.5  IPI01012504  PGD 6‐phosphogluconate dehydrogenase, decarboxylating  PGD  2  1.62  2.02  2.04  2.56  1.02  2.03  0.0048 
71  3.53  10.3  IPI00947363  DDX5 cDNA FLJ53366, highly similar to Probable ATP‐dependent RNA helicase DDX5  DDX5  2  2.05  1.88  2.69  2.45  1.17  2.25  0.0022 
72  3.47  25.1  IPI01011282  RANP1;RAN Uncharacterized protein  RANP1  2  2.09  2.18  2.36  2.46  1.18  2.27  0.0002 
73  2.97  20.9  IPI00655650  RPS26 40S ribosomal protein S26  RPS26  2  2.15  2.60  2.58  3.13  1.38  2.59  0.0011 
74  2.89  6.9  IPI00926491  PTCD1 cDNA FLJ56092, highly similar to Pentatricopeptide repeat protein 1  PTCD1  2  4.34  3.97  5.29  4.86  2.20  4.59  0.0002 
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